Primary Site >> Colorectal Cancer
Gene >> KRAS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Colon carcinoma K-ras 2 oncogene of a familial polyposis coli patient. PMID: 3021699 |
Ref: Prognostic implications of expression of the cellular genes myc, fos, Ha-ras and Ki-ras in colon carcinoma. PMID: 3040597 Ref: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. PMID: 3041218 Ref: c-K-ras mutations in human carcinomas occur preferentially in codon 12. PMID: 3330777 Ref: Overexpression of ras in mucus-secreting human colon carcinoma cells of low tumorigenicity. PMID: 3594436 |
Ref: A study of ras gene mutations in colonic adenomas from familial polyposis coli patients. PMID: 2577869 Ref: [Oncogene expression in colonic cancers]. PMID: 3051685 |
Ref: Multiple genetic alterations in distal and proximal colorectal cancer. PMID: 2569552 Ref: Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. PMID: 2648401 Ref: Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. PMID: 2649235 Ref: Detection of ras gene alterations and ras proteins in colorectal cancer. PMID: 2666051 Ref: Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. PMID: 2743265 |
Ref: Rearrangement, amplification and overexpression of c-Ha Ras gene in premalignant lesion of Turcot's syndrome. PMID: 1703248 Ref: [Molecular pathological diagnosis of cancer]. PMID: 1973345 Ref: K-ras activation in colorectal tumors from patients with familial polyposis coli. PMID: 2159840 Ref: Lessons from the genetics of colon cancer. PMID: 2173130 Ref: Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. PMID: 2187599 Ref: [A joint study of mutation of the Ki-ras oncogene and overexpression of the Tp53 oncogene in colorectal cancer]. PMID: 2190855 Ref: c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. PMID: 2194896 Ref: K-ras mutations (codon 12) are not involved in down-regulation of MHC class-I genes in colon carcinomas. PMID: 2203688 Ref: Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. PMID: 2404571 |
Ref: Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. PMID: 1652568 Ref: Evidence for a common molecular pathogenesis in colorectal, gastric, and pancreatic cancer. PMID: 1663781 Ref: Analysis of ras gene mutations in gastrointestinal cancers. PMID: 1686883 Ref: Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. PMID: 1773797 Ref: [Diagnosis of colorectal cancer from DNA level]. PMID: 1846282 Ref: [Cytomolecular aspects of colorectal carcinoma]. PMID: 1849388 Ref: c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. PMID: 1854618 Ref: Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. PMID: 1886718 Ref: [Prevalence of K-ras gene mutations in human colorectal cancers]. PMID: 1942608 Ref: Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. PMID: 1959991 Ref: A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction. PMID: 2017878 Ref: K-ras activation in gastric epithelial tumors in Japanese. PMID: 2049776 |
Ref: Colorectal carcinoma as a genetic phenomenon. PMID: 1294935 Ref: Multistage carcinogenesis in paediatric and adult cancers. PMID: 1314630 Ref: [Genetic analysis of adenomatous polyposis coli: analysis of alterations of oncogenes and tumor suppressor genes in colorectal tumors]. PMID: 1317336 Ref: K-ras gene mutations in adenomas and carcinomas of the colon. PMID: 1341261 Ref: Expression of p53 protein in invasive colorectal carcinomas of different histologic types. PMID: 1451054 Ref: Genetic changes in multi-step development of colorectal cancer. PMID: 1453686 Ref: Oncogenesis in ovarian cancer. PMID: 1502889 Ref: NIH3T3 transfectant containing human K-ras oncogene shows enhanced metastatic activity after in vivo tumor growth or co-culture with fibroblasts. PMID: 1505125 Ref: Lack of ras mutations and prediction of long-term survival in carcinoma of the colon. PMID: 1574489 Ref: K-ras oncogene mutations in rat colon tumors induced by N-methyl-N-nitrosourea. PMID: 1733572 |
Ref: [Cell kinetics of colorectal tumors with assessment by K-ras mutation and PCNA labeling index]. PMID: 7903793 Ref: K-ras point mutations in routinely processed tissues: non-radioactive screening by single strand conformational polymorphism analysis. PMID: 8157747 Ref: K-ras mutations in putative preneoplastic lesions in human colon. PMID: 8246286 Ref: Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. PMID: 8249918 Ref: [Sensitive detection of K-ras oncogene codon 12 mutations by nested PCR using mismatched primers and selective digestion of non-mutated PCR fragments with restriction enzyme]. PMID: 8254964 Ref: Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas. PMID: 8264230 Ref: Mutational heterogeneity among individual tumors in a case of multiple primary malignancy of the colon. PMID: 8283788 Ref: Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). PMID: 8318987 Ref: Rare frequency of activation of the Ki-ras gene in rat colon tumors induced by heterocyclic amines: possible alternative mechanisms of human colon carcinogenesis. PMID: 8352890 Ref: Loss of heterozygosity and K-ras gene mutations in gastric cancer. PMID: 8406432 Ref: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. PMID: 8419262 Ref: Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. PMID: 8421601 Ref: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. PMID: 8465203 Ref: Tumour suppressor genes and colorectal neoplasia. PMID: 8471756 Ref: Clues to the pathogenesis of familial colorectal cancer. PMID: 8484121 Ref: Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. PMID: 8486427 Ref: Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. PMID: 8495305 Ref: Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. PMID: 8515492 Ref: Mutations in the p53 suppressor gene do not correlate with C-k-ras oncogene mutations in colorectal-cancer. PMID: 21573526 |
Ref: [Etiology of colorectal cancer]. PMID: 7557283 Ref: c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. PMID: 7654441 Ref: Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. PMID: 7828987 Ref: [Transformation of NIH/3T3 cells and SW 480 cells displaying K-ras mutation]. PMID: 7882132 Ref: Relation between the occurrence of K-ras gene point mutations and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. PMID: 7913423 Ref: The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. PMID: 7970729 Ref: Ki-ras and c-myc oncogene expression measured by coamplification polymerase chain reaction. PMID: 8002989 Ref: Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. PMID: 8007010 Ref: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. PMID: 8012953 Ref: Microsatellite instability in sporadic endometrial carcinoma. PMID: 8040889 Ref: [Genetic alterations of human colorectal cancer]. PMID: 8109990 Ref: K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. PMID: 8160776 Ref: Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. PMID: 8187064 Ref: [Molecular oncological study on DNA ploidy, Ki-ras point mutation, and p21 expression in colorectal cancer]. PMID: 8196591 Ref: Detection of k-ras mutation in normal and malignant colonic tissues by an enriched PCR method. PMID: 21566936 Ref: Detection of ki-ras mutation in nonneoplastic mucosa of Japanese patients with colorectal cancers. PMID: 21566937 Ref: The overexpression of the sialyl-lewis(x) moiety is an independent and a more consistent marker of colon carcinogenesis than the overexpression of C-myc and ki-ras oncogenes. PMID: 21567012 Ref: Activating mutations in the k-ras gene in ulcerative-colitis and crohns-disease. PMID: 21607401 |
Ref: [Determination of the activated proto-oncogene (Ki-ras) in feces. A new laboratory analysis for early diagnosis of colorectal cancer]. PMID: 7482456 Ref: Adenoma-carcinoma sequence of colorectum. Prevalence of K-ras gene mutation in adenomas with increasing degree of dysplasia and aneuploidy. PMID: 7493139 Ref: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. PMID: 7553632 Ref: Molecular genetics of dysplasia in ulcerative colitis. PMID: 7577015 Ref: Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. PMID: 7579559 Ref: Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. PMID: 7593201 Ref: Somatic mutations of the adenomatous polyposis coli gene in gastroduodenal tumors from patients with familial adenomatous polyposis. PMID: 7606737 Ref: Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice. PMID: 7634980 Ref: Tumour diagnosis by PCR-based detection of tumour cells. PMID: 7652485 Ref: Using biopsy materials to detect mutations in gastrointestinal tumors. PMID: 7665812 Ref: The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. PMID: 7674088 Ref: K-ras gene mutations in early colorectal cancer ... flat elevated vs polyp-forming cancer.... PMID: 7731692 Ref: Overexpression of protein kinase C beta 1 in the SW480 colon cancer cell line causes growth suppression. PMID: 7767974 Ref: Ras oncogene and p53 gene hotspot mutations in colorectal cancers. PMID: 7787154 Ref: K-ras status does not predict successful hepatic resection of colorectal cancer metastasis. PMID: 7802584 Ref: The genetic basis of colorectal cancer--clinical implications. PMID: 7851569 Ref: Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. PMID: 7890240 Ref: Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. PMID: 8531010 Ref: Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis. PMID: 8563883 Ref: [Prognostic value of K-ras gene mutation in colorectal cancer]. PMID: 8581817 Ref: Molecular biology of colon polyps and colon cancer. PMID: 8607008 Ref: Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. PMID: 8612201 Ref: Multistep carcinogenesis in colorectal cancers. PMID: 8629105 Ref: Clonal analysis of colorectal tumors using K-ras and p53 gene mutations as markers. PMID: 8634782 Ref: Emergent issues in the genetics of intestinal neoplasia. PMID: 8718526 Ref: Sampling method as a key factor in identifying K-ras oncogene mutations in preneoplastic colorectal lesions. PMID: 8925520 Ref: Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival PMID: 9816002 Ref: A rapid PCR ELISA for the detection of activated K-ras in colorectal cancer. PMID: 16696021 Ref: K-ras mutation in colorectal carcinomas from singapore. PMID: 21556523 Ref: Alterations of p53 and k-ras genes in human colorectal-cancer with ulcerative-colitis. PMID: 21556601 |
Ref: Contributions of molecular genetics to the clinical management of colorectal cancer. PMID: 8554121 Ref: Frequent K-ras mutations in small bowel adenocarcinomas. PMID: 8565742 Ref: Fine mapping of colon tumor susceptibility (Scc) genes in the mouse, different from the genes known to be somatically mutated in colon cancer. PMID: 8577718 Ref: Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. PMID: 8608570 Ref: Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. PMID: 8621253 Ref: Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. PMID: 8623934 Ref: K-ras mutation in a tubular adenoma originating at an ileostomy in a familial adenomatous polyposis patient. PMID: 8633516 Ref: Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester. PMID: 8634090 Ref: A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. PMID: 8642788 Ref: Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. PMID: 8646513 Ref: Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. PMID: 8649851 Ref: A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. PMID: 8682594 Ref: Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. PMID: 8692875 Ref: Maintenance of growth factor signaling through Ras in human colon carcinoma cells containing K-ras mutations. PMID: 8759614 Ref: Clinical significance of K-ras oncogene activation in ampullary neoplasms. PMID: 8763258 Ref: Double cancer in a 74-year-old woman: a case report with genetic findings. PMID: 8804161 Ref: Inhibition of apoptosis in colon tumors induced in the rat by 2-amino-3-methylimidazo[4,5-f]quinoline. PMID: 8813112 Ref: Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). PMID: 8818652 Ref: Detection of rare circulating human colon tumor cells in a nude mouse xenograft model. PMID: 8827058 Ref: [Recent progress of molecular oncology and its contribution to clinical gastroenterology]. PMID: 8920648 Ref: The cellular and molecular pathogenesis of colorectal cancer. PMID: 8960890 Ref: Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. PMID: 8971180 Ref: Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. PMID: 9014854 Ref: K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. PMID: 9042267 Ref: Prediction of Biologic Aggressiveness in Colorectal Cancer by p53/K-ras-2 Topographic Genotyping. PMID: 10330194 Ref: Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. PMID: 10851498 Ref: Genetics of colorectal cancer (Review). PMID: 21541519 Ref: Mutation in the K-ras gene at codon 12 does not correlate with disease progression in colorectal carcinoma patients treated with 5-FU/folinic acid biomodulated chemotherapy. PMID: 21541641 |
Ref: Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. PMID: 8993798 Ref: K-ras mutations and prognosis in large-bowel carcinomas. PMID: 9018769 Ref: K-ras and p53 mutations in hereditary non-polyposis colorectal cancers. PMID: 9036876 Ref: Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. PMID: 9070487 Ref: Overexpression of SAP-1, a transmembrane-type protein tyrosine phosphatase, in human colorectal cancers. PMID: 9070877 Ref: Ki-ras point mutation in different types of colorectal carcinomas in early stages. PMID: 9075750 Ref: Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. PMID: 9137104 Ref: Frequency and clinico-pathological associations of ras mutations in colorectal cancer in the Victorian population. PMID: 9152150 Ref: K-ras mutation and loss of heterozygosity of chromosome 17p and survival in colorectal cancer. PMID: 9152151 Ref: Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. PMID: 9177704 Ref: K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. PMID: 9192830 Ref: Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. PMID: 9210960 Ref: [Findings of genetic changes in small intestinal carcinomas]. PMID: 9263525 Ref: Detection of colorectal cancer K-ras mutations using a simplified oligonucleotide ligation assay. PMID: 9328563 Ref: Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). PMID: 9345343 Ref: Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. PMID: 9346938 Ref: A newly identified pattern of K-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. PMID: 9347854 Ref: In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. PMID: 9352861 Ref: Activated Ki-ras enhances sensitivity of ceramide-induced apoptosis without c-Jun NH2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells. PMID: 9354428 Ref: Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells. PMID: 9376258 Ref: Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin beta1-chain maturation in colon epithelial cells. PMID: 9388239 Ref: Detection of tumour DNA in serum of colorectal cancer patients. PMID: 9397491 Ref: Colorectal carcinoma in Hong Kong: epidemiology and genetic mutations. PMID: 9413950 Ref: No involvement of APC gene mutations in ulcerative colitis-associated rat colon carcinogenesis induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate. PMID: 9433483 Ref: [P21-ras protein in tumors of the large intestine]. PMID: 9446408 Ref: Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. PMID: 9470817 Ref: Molecular analysis in endometrial cancer. PMID: 9474873 Ref: Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. PMID: 9514698 Ref: Combined analysis of microsatellite instability and K-ras mutation increases detection incidence of normal samples from colorectal cancer patients. PMID: 9815826 Ref: Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding PMID: 10851492 Ref: Suppression of serum-induced c-jun expression by activated Ki-ras in human colon cancer cells. PMID: 12503187 Ref: ras and myc analysis in primary and metastatic colorectal carcinomas. PMID: 21533375 |
Ref: MHC class I bound peptides of a colon carcinoma cell line, a Ki-ras gene-targeted progeny cell line and a B cell line. PMID: 9489488 Ref: Molecular pathogenesis of sporadic duodenal cancer. PMID: 9514055 Ref: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. PMID: 9515799 Ref: Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. PMID: 9520413 Ref: Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. PMID: 9533753 Ref: Molecular detection of genetic alterations in the serum of colorectal cancer patients. PMID: 9537240 Ref: The type of K-ras mutation determines prognosis in colorectal cancer. PMID: 9560119 Ref: Immunoperoxidase staining for cytokeratins 8 and 18 is very sensitive for detection of occult node metastasis of colorectal cancer: a comparison with genetic analysis of K-ras. PMID: 9568504 Ref: The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. PMID: 9579832 Ref: Molecular approaches for colorectal cancer screening. PMID: 9585023 Ref: Role of K-ras mutations in colorectal carcinoma. PMID: 9585064 Ref: Genetic alterations in a patient with Turcot's syndrome. PMID: 9589476 Ref: Growth patterns and genetic changes of colorectal carcinoma. PMID: 9614443 Ref: Detection of K-ras point mutations in the supernatants of peritoneal and pleural effusions for diagnosis complementary to cytologic examination. PMID: 9620027 Ref: Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. PMID: 9626054 Ref: Primary cancer of the small intestine and mutational analysis of the K-ras and p53 genes. PMID: 9658320 Ref: [Genetic alterations and molecular mechanisms underlying colorectal tumorigenesis]. PMID: 9676181 Ref: [Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer]. PMID: 9695076 Ref: K-ras codon 12 mutation determines the polypoid growth of colorectral cancer. PMID: 9699657 Ref: Differential activation of the c-Ki-ras-2 proto-oncogene in human colorectal carcinoma. PMID: 9703874 Ref: Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. PMID: 9708798 Ref: Ki-ras mutations and prognosis in colorectal cancer. PMID: 9713302 Ref: Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. PMID: 9713338 Ref: Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. PMID: 9732698 Ref: Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. PMID: 9777938 Ref: Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization. PMID: 9778456 Ref: Long-term analysis of colonic aberrant crypt formation after treatment of Sprague-Dawley rats with azoxymethane. PMID: 9804274 Ref: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. PMID: 9810004 Ref: [Analysis of genetic disorders of cancer of the rectum: differences in relation to cancer of the colon]. PMID: 9823556 Ref: Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Ras in colon carcinoma cells. PMID: 9829751 Ref: Endogenous TNF inducibility and prognosis of colorectal cancer. PMID: 9891459 Ref: Ki-ras codon 12 point mutational activation in Hong Kong colorectal carcinoma patients. PMID: 10025877 Ref: Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: a relationship with tumor phenotype and survival. PMID: 10076772 |
Ref: Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. PMID: 9923541 Ref: Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. PMID: 9926917 Ref: Symptomatic colonic polyps in childhood: not so benign. PMID: 9932851 Ref: Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum. PMID: 9988229 Ref: L-myc genotypes in Hong Kong Chinese colorectal carcinoma patients. PMID: 10023018 Ref: [Genetic alterations in human malignant tumor]. PMID: 10067361 Ref: p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. PMID: 10334521 Ref: Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells. PMID: 10344756 Ref: Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection. PMID: 10370622 Ref: Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. PMID: 10370632 Ref: K-ras mutation and loss of heterozygosity of the adenomatous polyposis coli gene in patients with colorectal adenomas with in situ carcinoma. PMID: 10391560 Ref: Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. PMID: 10398103 Ref: Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. PMID: 10408710 Ref: [Establishment of alpha-fetoprotein producing human rectal cancer cell line (RKK-YK) and its features]. PMID: 10434556 Ref: Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. PMID: 10461063 Ref: [Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer]. PMID: 10461447 Ref: Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. PMID: 10471035 Ref: c-Ki-ras mutations in colorectal adenocarcinomas from a country with a rapidly changing colorectal cancer incidence. PMID: 10496348 Ref: Colorectal cancer with and without microsatellite instability involves different genes. PMID: 10502323 Ref: Cell cycle variations in azoxymethane-induced rat colorectal carcinogenesis studied by flow cytometry. PMID: 10523722 Ref: Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. PMID: 10537293 Ref: Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. PMID: 10537295 Ref: Molecular pathology of colorectal cancer. PMID: 10545700 Ref: A case of adenocarcinoma of the small intestine in a Japanese patient with Crohn disease: a report with immunohistochemical and oncogenic analyses. PMID: 10582770 Ref: [Detection of K-ras mutations in colon cancer by PHA-PHFA (preferential homoduplex formation assay)]. PMID: 10590684 Ref: Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. PMID: 10595736 Ref: Multiple APC mutations in sporadic flat colorectal adenomas. PMID: 10602369 Ref: Renaissance mummies in Italy. PMID: 11624203 |
Ref: Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas. PMID: 10612810 Ref: Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. PMID: 10644313 Ref: Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. PMID: 10657973 Ref: pS2 expression as a possible diagnostic marker of colorectal carcinoma in ulcerative colitis. PMID: 10671663 Ref: Chronic inflammatory bowel disease and cancer. PMID: 10690586 Ref: Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. PMID: 10696887 Ref: Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon. PMID: 10708483 Ref: Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. PMID: 10732765 Ref: Utilization of K-ras mutations identified in stool DNA for the early detection of colorectal cancer. PMID: 10762013 Ref: Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. PMID: 10766356 Ref: Colitis-related rat colon carcinogenesis induced by 1-hydroxy-anthraquinone and methylazoxymethanol acetate (Review). PMID: 10767359 Ref: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. PMID: 10811111 Ref: Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. PMID: 10841827 Ref: Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. PMID: 10873061 Ref: p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. PMID: 10884918 Ref: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. PMID: 10885605 Ref: [Characteristics of plasma DNA and its application for detection of K-ras gene mutation]. PMID: 10897674 Ref: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. PMID: 10928094 Ref: Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. PMID: 10952790 Ref: Clinical value of bile for the detection of mutant K-ras from colorectal liver metastases. PMID: 10953312 Ref: Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. PMID: 10956407 Ref: Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. PMID: 10972292 Ref: K-ras and p53 mutations in DNA extracted from colonic epithelial cells exfoliated in faeces of patients with colorectal cancer. PMID: 10975788 Ref: Colorectal carcinogenesis based on molecular biology of early colorectal cancer, with special reference to nonpolypoid (superficial) lesions. PMID: 11036287 Ref: Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. PMID: 11051374 Ref: A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. PMID: 11055588 Ref: ["Field cancerization"--an additional phenomenon in development of colon tumors? K-ras codon 12 mutations in normal colonic mucosa of patients with colorectal neoplasms]. PMID: 11077584 Ref: Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. PMID: 11097222 Ref: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. PMID: 11097226 Ref: Analysis of K-ras codon 12 mutations and p53 overexpression in colorectal nodule-aggregating tumors. PMID: 11106095 Ref: Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. PMID: 11118042 Ref: Pathogenesis of non-familial colorectal carcinomas with high microsatellite instability. PMID: 11127266 Ref: Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. PMID: 11129419 Ref: Flat-elevated and depressed, subtypes of flat early colorectal cancers, should be distinguished by their pathological features. PMID: 11151430 Ref: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. PMID: 11156386 Ref: Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. PMID: 11156393 Ref: Molecular detection of codon 12 K-RAS mutations in circulating DNA from serum of colorectal cancer patients. PMID: 11192825 Ref: Use of p53 transgenic mice in the development of cancer models for multiple purposes. PMID: 11195457 Ref: Differential sensitivity to lung tumorigenesis following transplacental exposure of mice to polycyclic hydrocarbons, heterocyclic amines, and lung tumor promoters. PMID: 11195466 Ref: A double germline mutations in the APC and p53 genes. PMID: 11263856 Ref: Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. PMID: 11310641 |
Ref: Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. PMID: 11029459 Ref: K-ras mutation detection by hybridization to a polypyrrole DNA chip. PMID: 11159765 Ref: Hyperplastic polyposis: association with colorectal cancer. PMID: 11176066 Ref: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. PMID: 11208819 Ref: Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. PMID: 11237496 Ref: Molecular changes in the Ki-ras and APC genes in colorectal adenomas and carcinomas arising in the same patient. PMID: 11241408 Ref: Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. PMID: 11289281 Ref: Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. PMID: 11319909 Ref: Biomarkers for early detection of colon cancer. PMID: 11350874 Ref: Tumour-derived mutated K-ras codon 12 expression in regional lymph nodes of stage II colorectal cancer patients is not associated with increased risk of cancer-related death. PMID: 11355316 Ref: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. PMID: 11358818 Ref: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. PMID: 11387355 Ref: Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. PMID: 11406538 Ref: Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. PMID: 11407514 Ref: Detection of the mutated K-Ras biomarker in colorectal carcinoma. PMID: 11418008 Ref: K-ras and p53 mutations in colonic lavage fluid of patients with colorectal neoplasias. PMID: 11435722 Ref: Melting temperature analysis as quantitative method for detection of point mutations. PMID: 11506461 Ref: K-ras mutational analysis of polyclonal colorectal cancers identifies uniclonal circulating tumor cells. PMID: 11510588 Ref: A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. PMID: 11735295 Ref: Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. PMID: 11745689 Ref: Analysis of Ki-ras gene mutations associated with DNA diploid, aneuploid, and multiploid colorectal carcinomas using a crypt isolation technique. PMID: 11754204 Ref: APC and K-ras gene mutation in aberrant crypt foci of human colon. PMID: 11819789 Ref: [Mutations of APC and K-ras gene in aberrant crypt foci from human colon]. PMID: 11866955 Ref: Lessons learned from colorectal model of tumourigenesis. PMID: 11957250 |
Ref: Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer. PMID: 11854698 Ref: Associations between family history of colorectal cancer and genetic alterations in tumors. PMID: 11857362 Ref: A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. PMID: 11880119 Ref: Frequent polymorphism of peroxisome proliferator activated receptor gamma gene in colorectal cancer containing wild-type K-ras gene. PMID: 11956653 Ref: Prognostic significance of p53 mutations in colon cancer at the population level. PMID: 11992552 Ref: Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries. PMID: 12009696 Ref: Frequent detection of K-ras mutation in stool samples of colorectal carcinoma patients after improved DNA extraction: comparison with tissue samples. PMID: 12012008 Ref: Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. PMID: 12016117 Ref: Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. PMID: 12017282 Ref: K-ras mutations and RASSF1A promoter methylation in colorectal cancer. PMID: 12032847 Ref: High apoptotic activity and low epithelial cell proliferation with underexpression of p21(WAF1/CIP1) and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type. PMID: 12047142 Ref: Colorectal carcinoma with special reference to growth pattern classifications: clinicopathologic characteristics and genetic changes. PMID: 12051534 Ref: Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. PMID: 12081197 Ref: Increased frequency of p53 mutation in sporadic colorectal cancer from cigarette smokers. PMID: 12110635 Ref: Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. PMID: 12110640 Ref: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. PMID: 12124803 Ref: Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. PMID: 12145803 Ref: Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane. PMID: 12148579 Ref: GSTM-1 and NAT2 and genetic alterations in colon tumors. PMID: 12195642 Ref: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. PMID: 12198537 Ref: Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. PMID: 12207005 Ref: Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. PMID: 12360473 Ref: Predominance of CIN versus MSI in the development of rectal cancer at young age. PMID: 12379157 Ref: Molecular validation of the modified Vienna classification of colorectal tumors. PMID: 12411586 Ref: DNA alkylation and repair in the large bowel: animal and human studies. PMID: 12421880 Ref: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. PMID: 12438234 Ref: Detection of tumor DNA in serum of colorectal cancer patients. PMID: 12460469 |
Ref: Methylation profile of the MLH1 promoter region and their relationship to colorectal carcinogenesis. PMID: 12461746 Ref: A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. PMID: 12477769 Ref: Exploring environmental causes of altered ras effects: fragmentation plus integration? PMID: 12557259 Ref: CpG island methylation is a common finding in colorectal cancer cell lines. PMID: 12569385 Ref: Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. PMID: 12592366 Ref: Telomeric repeat-length alterations in colorectal carcinoma are associated with loss of heterozygosity and point mutation in p53 gene. PMID: 12632102 Ref: Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. PMID: 12651912 Ref: Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis. PMID: 12652573 Ref: Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. PMID: 12696070 Ref: Evaluation of K-RAS gene in colorectal cancer. PMID: 12722796 Ref: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. PMID: 12727799 Ref: Murine models of colorectal cancer: studying the role of oncogenic K-ras. PMID: 12737309 Ref: Tage4/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration. PMID: 12740392 Ref: Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. PMID: 12777192 Ref: Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. PMID: 12782759 Ref: [Study of angiogenesis in human colorectal carcinoma and its modulation by p53 and K-ras gene]. PMID: 12783699 Ref: Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene. PMID: 12792735 Ref: Expression profiling of CC531 colon carcinoma cells reveals similar regulation of beta-catenin target genes by both butyrate and aspirin. PMID: 12800193 Ref: Distribution of genetic variants in preneoplastic areas of colorectal tumours. PMID: 12875854 Ref: Lignan precursors from flaxseed or rye bran do not protect against the development of intestinal neoplasia in ApcMin mice. PMID: 12881015 Ref: Transitions and transversions in Ki-ras gene in colorectal cancers in Mexican patients. PMID: 12908779 Ref: beta-Catenin and ras oncogenes detect most human colorectal cancer. PMID: 12912959 Ref: Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. PMID: 12915883 Ref: BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. PMID: 12941809 Ref: Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. PMID: 12972432 Ref: Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. PMID: 14500348 Ref: High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. PMID: 14506738 Ref: Analysis of Ki-ras and p53 gene mutations in laterally spreading tumors of the colorectum. PMID: 14629748 Ref: Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma. PMID: 14654549 Ref: Aberrant crypt foci as microscopic precursors of colorectal cancer. PMID: 14669304 Ref: Genetic analysis of radiation-associated rectal cancer. PMID: 14714259 Ref: Analysis of beta-catenin, Ki-ras, and microsatellite stability in azoxymethane-induced colon tumors of BDIX/Orl Ico rats. PMID: 14727811 |
Ref: Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. PMID: 14603530 Ref: Deregulated expression of KRAP, a novel gene encoding actin-interacting protein, in human colon cancer cells. PMID: 14673706 Ref: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. PMID: 14688025 Ref: o-Nitrotoluene-induced large intestinal tumors in B6C3F1 mice model human colon cancer in their molecular pathogenesis. PMID: 14688030 Ref: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. PMID: 14695993 Ref: Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. PMID: 14734479 Ref: MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. PMID: 14750179 Ref: Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. PMID: 14750214 Ref: K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues. PMID: 14764072 Ref: Quantitative detection of mutant alleles of the K-ras gene with minor groove binder-conjugated fluorogenic DNA probes. PMID: 14767554 Ref: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. PMID: 14991899 Ref: Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. PMID: 14996738 Ref: Role of inherited defects of MYH in the development of sporadic colorectal cancer. PMID: 15034862 Ref: Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. PMID: 15037663 Ref: Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. PMID: 15069679 Ref: Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. PMID: 15096565 Ref: Fat and K-ras mutations in sporadic colorectal cancer in The Netherlands Cohort Study. PMID: 15117813 Ref: RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. PMID: 15118616 Ref: K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. PMID: 15138598 Ref: p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. PMID: 15172127 Ref: Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. PMID: 15194222 Ref: Pathological features and genetic alterations in colorectal carcinomas with characteristics of nonpolypoid growth. PMID: 15213719 Ref: Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas. PMID: 15235871 Ref: Decrease in specific micronutrient intake in colorectal cancer patients with tumors presenting Ki-ras mutation. PMID: 15274393 Ref: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. PMID: 15294875 Ref: Association of K-ras mutations with liver metastases from colorectal carcinoma. PMID: 15330200 Ref: Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. PMID: 15333653 Ref: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. PMID: 15476557 Ref: BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. PMID: 15489648 Ref: Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. PMID: 15513360 Ref: Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. PMID: 15534934 Ref: p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. PMID: 15536342 Ref: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. PMID: 15541358 Ref: Genomic heterogeneity and instability in colorectal cancer: spectral karyotyping, glutathione transferase-Ml and ras. PMID: 15542115 Ref: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. PMID: 15542810 Ref: Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. PMID: 15555207 Ref: Mutation of beta-catenin does not coexist with K-ras mutation in colorectal tumorigenesis. PMID: 15573917 Ref: Cyclooxygenase-2 overexpression is related to polypoid growth and K-ras gene mutation in T1 colorectal carcinomas. PMID: 15622585 Ref: Clinical usefulness of K-RAS mutation detection in colorectal cancer and in surgical margins of the colon. PMID: 15638373 |
Ref: Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas. PMID: 15316933 Ref: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. PMID: 15494427 Ref: Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. PMID: 15503135 Ref: Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. PMID: 15609319 Ref: Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. PMID: 15671526 Ref: Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. PMID: 15702478 Ref: Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. PMID: 15704157 Ref: Mapping of the critical region of mitogene-inducible gene-6 for NF-kappaB activation. PMID: 15706420 Ref: A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability. PMID: 15729700 Ref: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. PMID: 15729718 Ref: Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. PMID: 15735008 Ref: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. PMID: 15753357 Ref: Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. PMID: 15771905 Ref: Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. PMID: 15781617 Ref: Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. PMID: 15781646 Ref: Persistence of K-ras mutations in plasma after colorectal tumor resection. PMID: 15816642 Ref: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. PMID: 15863375 Ref: Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. PMID: 15923428 Ref: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. PMID: 15923430 Ref: Colorectal adenomas with a low frequency of ki-ras mutations: a sample from a population with a low mortality rate from colorectal cancer. PMID: 15932552 Ref: Molecular markers that predict response to colon cancer therapy. PMID: 15934813 Ref: Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. PMID: 15940626 Ref: Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. PMID: 15959913 Ref: The prevalence of PIK3CA mutations in gastric and colon cancer. PMID: 15994075 Ref: Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. PMID: 16007118 Ref: The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. PMID: 16012945 Ref: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. PMID: 16015629 Ref: Detection of single-base mutation by affinity capillary electrophoresis using a DNA-polyacrylamide conjugate. PMID: 16041699 Ref: MutYH (MYH) and colorectal cancer. PMID: 16042573 Ref: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. PMID: 16049314 Ref: [The expressions of K-ras in human laryngeal squamous cell carcinoma cell lines (Hep-2) and its significance]. PMID: 16075979 Ref: Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. PMID: 16077965 Ref: Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. PMID: 16091732 Ref: Control of colorectal metastasis formation by K-Ras. PMID: 16098678 Ref: Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. PMID: 16110022 Ref: Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. PMID: 16112461 Ref: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. PMID: 16127434 Ref: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. PMID: 16143123 Ref: Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. PMID: 16166287 Ref: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. PMID: 16166444 Ref: MGMT promoter methylation and field defect in sporadic colorectal cancer. PMID: 16174854 Ref: MTHFR variants reduce the risk of G:C->A:T transition mutations within the p53 tumor suppressor gene in colon tumors. PMID: 16177213 Ref: Venous invasion and down-regulation of p21(WAF1/CIP1) are associated with metastasis in colorectal carcinomas. PMID: 16201087 Ref: The Cables gene on chromosome 18Q regulates colon cancer progression in vivo. PMID: 16210915 Ref: Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? PMID: 16219426 Ref: Antisense gene therapy using anti-k-ras and antitelomerase oligonucleotides in colorectal cancer. PMID: 16262526 Ref: Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. PMID: 16282499 Ref: Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. PMID: 16322286 Ref: [Loss of heterozygosity on chromosome 12p12-13 region in Chinese patients with colon carcinoma]. PMID: 16331576 Ref: Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. PMID: 16356174 Ref: Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway. PMID: 16507412 Ref: Detection of a K-ras mutation in urine of patients with colorectal cancer. PMID: 17192038 |
Ref: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. PMID: 16118624 Ref: Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. PMID: 16152623 Ref: Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. PMID: 16158056 Ref: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. PMID: 16231316 Ref: Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. PMID: 16376301 Ref: BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. PMID: 16381005 Ref: BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. PMID: 16403224 Ref: CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. PMID: 16407376 Ref: Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. PMID: 16448675 Ref: Aberrant crypt foci. PMID: 16475686 Ref: PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). PMID: 16489531 Ref: RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. PMID: 16505104 Ref: Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients. PMID: 16534842 Ref: Immunosuppression promotes reovirus therapy of colorectal liver metastases. PMID: 16543920 Ref: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. PMID: 16618717 Ref: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. PMID: 16619509 Ref: Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. PMID: 16645205 Ref: Coexistence of K-ras mutations and HPV infection in colon cancer. PMID: 16672071 Ref: Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. PMID: 16699497 Ref: KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. PMID: 16707468 Ref: Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. PMID: 16760301 Ref: Uranyl nitrilotriacetate, a stabilized salt of uranium, is genotoxic in nontransformed human colon cells and in the human colon adenoma cell line LT97. PMID: 16840563 Ref: Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. PMID: 16850502 Ref: Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. PMID: 16879389 Ref: Do MSI-L sporadic colorectal tumors develop through "mild mutator pathway"? PMID: 16891863 Ref: Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. PMID: 16900509 Ref: Relationship between point gene mutation, chromosomal abnormality, and tumour suppressor gene methylation status in colorectal adenomas. PMID: 16902913 Ref: Alcohol and the risk of colon and rectal cancer with mutations in the K-ras gene. PMID: 16905440 Ref: Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. PMID: 16918136 Ref: K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. PMID: 16918139 Ref: Adequacy of colonoscopic biopsy specimens for molecular analysis: a comparative study with colectomy tissue. PMID: 16932072 Ref: Recurrent KRAS codon 146 mutations in human colorectal cancer. PMID: 16969076 Ref: Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. PMID: 16969349 Ref: KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. PMID: 16988471 Ref: APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. PMID: 17030180 Ref: CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. PMID: 17065427 Ref: Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. PMID: 17082247 Ref: Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. PMID: 17089045 Ref: Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy. PMID: 17105421 Ref: Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. PMID: 17122504 Ref: Promoter methylation precedes chromosomal alterations in colorectal cancer development. PMID: 17167178 Ref: Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. PMID: 17177160 Ref: Colorectal cancer: a multipathway disease. PMID: 17425506 Ref: Types of colorectal adenoma. PMID: 17867575 Ref: [The Aragonese mummies of the Basilica of Saint Domenico Maggiore in Naples]. PMID: 18175625 |
Ref: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. PMID: 16953233 Ref: Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. PMID: 17086168 Ref: Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. PMID: 17130841 Ref: Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. PMID: 17133351 Ref: Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. PMID: 17149612 Ref: Characterization of a novel oncogenic K-ras mutation in colon cancer. PMID: 17150185 Ref: Colorectal cancer: potential therapeutic benefits of Vitamin D. PMID: 17157547 Ref: Comet fluorescence in situ hybridization analysis for oxidative stress-induced DNA damage in colon cancer relevant genes. PMID: 17192441 Ref: Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human. PMID: 17200209 Ref: Expression analysis of pancreatic cancer cell lines reveals association of enhanced gene transcription and genomic amplifications at the 8q22.1 and 8q24.22 loci. PMID: 17203180 Ref: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. PMID: 17204026 Ref: Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. PMID: 17237286 Ref: Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. PMID: 17239930 Ref: Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC). PMID: 17240321 Ref: Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. PMID: 17258725 Ref: Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. PMID: 17260021 Ref: Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. PMID: 17267619 Ref: TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. PMID: 17270239 Ref: Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. PMID: 17290389 Ref: APC mutations and other genetic and epigenetic changes in colon cancer. PMID: 17293392 Ref: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. PMID: 17314276 Ref: BMP-induced growth suppression in colon cancer cells is mediated by p21WAF1 stabilization and modulated by RAS/ERK. PMID: 17317101 Ref: Mutant-enriched PCR and allele-specific hybridization reaction to detect K-ras mutations in stool DNA: high prevalence in a large sample of older adults. PMID: 17317884 Ref: Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. PMID: 17339237 Ref: Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. PMID: 17350669 Ref: Chromosomal 20q gain in the DNA diploid component of aneuploid colorectal carcinomas. PMID: 17354231 Ref: Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. PMID: 17390050 Ref: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. PMID: 17393356 Ref: Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. PMID: 17410283 Ref: Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. PMID: 17440063 Ref: Targeting aberrant chromatin structure in colorectal carcinomas. PMID: 17464246 Ref: Histopathological and genetic differences between polypoid and non-polypoid submucosal colorectal carcinoma. PMID: 17465446 Ref: 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. PMID: 17474983 Ref: Molecular classification and genetic pathways in hyperplastic polyposis syndrome. PMID: 17503413 Ref: Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. PMID: 17516584 Ref: Limitations in molecular detection of lymph node micrometastasis from colorectal cancer. PMID: 17525678 Ref: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. PMID: 17565744 Ref: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. PMID: 17591929 Ref: MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. PMID: 17621591 Ref: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. PMID: 17625445 Ref: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. PMID: 17629419 Ref: Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes. PMID: 17636402 Ref: [Value of fecal and blood adenomatous polyposis coli gene and K-ras gene mutation detection in colorectal neoplasm screening]. PMID: 17666342 Ref: Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. PMID: 17693665 Ref: No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. PMID: 17697521 Ref: High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. PMID: 17707462 Ref: Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo. PMID: 17710156 Ref: DNA mutation detection with chip-based temperature gradient capillary electrophoresis using a slantwise radiative heating system. PMID: 17713615 Ref: P21WAF1/CIP1 expression in colorectal carcinomas is related to Kras mutations and prognosis. PMID: 17873613 Ref: Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. PMID: 17908962 Ref: Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. PMID: 17914558 Ref: Analysis of KRAP expression and localization, and genes regulated by KRAP in a human colon cancer cell line. PMID: 17934691 Ref: Hyperplastic and serrated polyps of the colorectum. PMID: 17996799 Ref: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. PMID: 18003927 Ref: Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. PMID: 18006820 Ref: [Genetic profile and molecular bases of pancreatic carcinogenesis]. PMID: 18028855 Ref: Flat colorectal cancers are genetically determined and progress to invasion without going through a polypoid stage. PMID: 18089788 Ref: The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. PMID: 18265644 |
Ref: Relationship of BRAF mutation, morphology, and apoptosis in early colorectal cancer. PMID: 17924122 Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. PMID: 18054006 Ref: SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. PMID: 18064648 Ref: WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 18084250 Ref: Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. PMID: 18097554 Ref: Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells. PMID: 18098284 Ref: BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. PMID: 18098337 Ref: Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G > T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. PMID: 18172263 Ref: Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. PMID: 18176934 Ref: Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). PMID: 18186519 Ref: Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. PMID: 18192688 Ref: Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. PMID: 18199160 Ref: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. PMID: 18202412 Ref: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. PMID: 18206383 Ref: [Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology]. PMID: 18210112 Ref: Differential Notch and TGFbeta signaling in primary colorectal tumors and their corresponding metastases. PMID: 18219106 Ref: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. PMID: 18224685 Ref: [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. PMID: 18230579 Ref: Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. PMID: 18240147 Ref: Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. PMID: 18259212 Ref: Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. PMID: 18271008 Ref: Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: results from the Netherlands Cohort Study. PMID: 18296105 Ref: Serrated polyps with "intermediate features" of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. PMID: 18300810 Ref: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. PMID: 18316791 Ref: Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation. PMID: 18361917 Ref: Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. PMID: 18372904 Ref: DxS Ltd. PMID: 18384259 Ref: Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. PMID: 18386236 Ref: The role of molecular markers in predicting response to therapy in patients with colorectal cancer. PMID: 18422373 Ref: [Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer]. PMID: 18431556 Ref: [K-ras mutation as a prognostic factor in colorectal carcinoma]. PMID: 18432074 Ref: Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. PMID: 18435933 Ref: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. PMID: 18437170 Ref: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. PMID: 18451217 Ref: Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. PMID: 18486467 Ref: Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab? PMID: 18487581 Ref: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. PMID: 18516290 Ref: Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. PMID: 18517279 Ref: In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. PMID: 18524847 Ref: Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? PMID: 18525343 Ref: A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. PMID: 18544172 Ref: p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. PMID: 18546269 Ref: Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. PMID: 18550572 Ref: The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine. PMID: 18554389 Ref: Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21. PMID: 18561895 Ref: Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance. PMID: 18567071 Ref: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. PMID: 18577988 Ref: RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. PMID: 18592002 Ref: B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. PMID: 18602919 Ref: Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. PMID: 18619647 Ref: Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. PMID: 18627290 Ref: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. PMID: 18628094 Ref: Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer? PMID: 18655729 Ref: KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS. PMID: 18669174 Ref: Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1. PMID: 18692554 Ref: Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3. PMID: 18771677 Ref: BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? PMID: 18782444 Ref: Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. PMID: 18794099 Ref: Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. PMID: 18798261 Ref: Significance of serrated polyps of the colon. PMID: 18799125 Ref: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. PMID: 18802721 Ref: [Molecular targets for colon cancer. VEGF, EGFR - and what else?]. PMID: 18810446 Ref: CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. PMID: 18834226 Ref: A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. PMID: 18843035 Ref: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. PMID: 18922929 Ref: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. PMID: 18946061 Ref: Cohort study of fatty acid synthase expression and patient survival in colon cancer. PMID: 18955444 Ref: Panitumumab: in metastatic colorectal cancer with wild-type KRAS. PMID: 18998757 Ref: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. PMID: 19001320 Ref: Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PMID: 19002263 Ref: [Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view]. PMID: 19004722 Ref: [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer]. PMID: 19004723 Ref: [Design of new protocols. Role of molecular biology units?]. PMID: 19004733 Ref: Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature. PMID: 19023234 Ref: A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. PMID: 19033568 Ref: Ligase detection reaction for the analysis of point mutations using free-solution conjugate electrophoresis in a polymer microfluidic device. PMID: 19053073 Ref: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. PMID: 19056857 Ref: [Effect of microRNA143 expression on cell proliferation in colonic carcinoma]. PMID: 19062714 Ref: KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition. PMID: 19078954 Ref: Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. PMID: 19087308 Ref: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. PMID: 19088039 Ref: First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. PMID: 19101405 Ref: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. PMID: 19117505 Ref: The role of targeted therapy in the treatment of advanced colorectal cancer. PMID: 19238551 Ref: Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. PMID: 19337429 Ref: Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). PMID: 19343143 Ref: KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. PMID: 19378369 Ref: Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer. PMID: 20445774 |
Ref: Use of Comet-FISH in the study of DNA damage and repair: review. PMID: 18304859 Ref: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. PMID: 18669866 Ref: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. PMID: 18767147 Ref: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. PMID: 18832519 Ref: Role of Necl-5 in the pathophysiology of colorectal lesions induced by dimethylhydrazine and/or dextran sodium sulphate. PMID: 18973187 Ref: Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations. PMID: 18980800 Ref: Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression. PMID: 18992247 Ref: Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. PMID: 18992263 Ref: High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. PMID: 19026650 Ref: KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. PMID: 19047277 Ref: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. PMID: 19047896 Ref: Setting future standards for KRAS testing in colorectal cancer. PMID: 19102707 Ref: Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. PMID: 19107228 Ref: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. PMID: 19117687 Ref: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. PMID: 19124802 Ref: Role of miR-143 targeting KRAS in colorectal tumorigenesis. PMID: 19137007 Ref: Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? PMID: 19144681 Ref: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. PMID: 19147861 Ref: [Biomarker for chemotherapy in patients with colorectal cancer]. PMID: 19151559 Ref: MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. PMID: 19164452 Ref: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. PMID: 19186181 Ref: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. PMID: 19188670 Ref: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. PMID: 19189371 Ref: Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. PMID: 19190129 Ref: TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. PMID: 19208363 Ref: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. PMID: 19223544 Ref: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. PMID: 19236713 Ref: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. PMID: 19237633 Ref: Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. PMID: 19273701 Ref: K-ras mutations in colorectal cancer: a practice changing discovery. PMID: 19274041 Ref: Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. PMID: 19303019 Ref: Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients. PMID: 19309232 Ref: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. PMID: 19339720 Ref: A molecular signature for Epithelial to Mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. PMID: 19340593 Ref: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. PMID: 19344998 Ref: KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. PMID: 19352138 Ref: Association of MICA-TM and MICB C1_2_A microsatellite polymorphisms with tumor progression in patients with colorectal cancer. PMID: 19353249 Ref: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. PMID: 19358724 Ref: Lung tumor promotion by curcumin. PMID: 19359593 Ref: KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. PMID: 19368524 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: [Molecular targeted therapy in colorectal cancer and its resistance]. PMID: 19381027 Ref: Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. PMID: 19386128 Ref: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. PMID: 19390304 Ref: Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. PMID: 19411318 Ref: Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. PMID: 19412426 Ref: [Frequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancer]. PMID: 19418727 Ref: Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. PMID: 19424571 Ref: Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. PMID: 19430299 Ref: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 19430421 Ref: A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. PMID: 19439077 Ref: Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes. PMID: 19442760 Ref: Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis. PMID: 19450806 Ref: A novel mutant allele specific amplification and electrochemiluminescence method for the detection of point mutation in clinical samples. PMID: 19450969 Ref: Tumor markers and rectal cancer: support for an inflammation-related pathway. PMID: 19452524 Ref: DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. PMID: 19470733 Ref: The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. PMID: 19471640 Ref: Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. PMID: 19474002 Ref: A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. PMID: 19478384 Ref: Genetics: Predictive value of KRAS mutations in chemoresistant CRC. PMID: 19483733 Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: A cohort study of p27 localization in colon cancer, body mass index, and patient survival. PMID: 19505918 Ref: A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. PMID: 19513025 Ref: Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. PMID: 19526592 Ref: Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. PMID: 19527492 Ref: Genetic prognostic and predictive markers in colorectal cancer. PMID: 19536109 Ref: Clinical biomarkers in oncology: focus on colorectal cancer. PMID: 19537845 Ref: [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy]. PMID: 19542725 Ref: KRAS mutation testing in colorectal cancer. PMID: 19546608 Ref: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. PMID: 19549773 Ref: Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma. PMID: 19569179 Ref: A comparison of colon and rectal somatic DNA alterations. PMID: 19571709 Ref: Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. PMID: 19574674 Ref: Genetic pathways to colorectal cancer. PMID: 19576232 Ref: [Panitumumab-treatment of metastatic colorectal cancer]. PMID: 19581179 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. PMID: 19581844 Ref: Treatment for colorectal liver metastases: a review. PMID: 19582473 Ref: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. PMID: 19584150 Ref: Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. PMID: 19584170 Ref: Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. PMID: 19597023 Ref: Are RAS mutations predictive markers of resistance to standard chemotherapy? PMID: 19597509 Ref: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. PMID: 19603018 Ref: [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]. PMID: 19620792 Ref: Genetic and molecular diversity of colon cancer hepatic metastases. PMID: 19628078 Ref: KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. PMID: 19632927 Ref: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. PMID: 19636327 Ref: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. PMID: 19637312 Ref: TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. PMID: 19637313 Ref: Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. PMID: 19644023 Ref: A novel K-ras mutation in colorectal cancer. A case report and literature review. PMID: 19661358 Ref: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. PMID: 19661383 Ref: Anti-EGFR therapy in colorectal cancer: how to choose the right patient. PMID: 19663767 Ref: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. PMID: 19666851 Ref: Microsatellite instability and survival in rectal cancer. PMID: 19669908 Ref: [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation]. PMID: 19671328 Ref: Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. PMID: 19671674 Ref: Oncogenic activating mutations are associated with local copy gain. PMID: 19671679 Ref: Integrative approach for prioritizing cancer genes in sporadic colon cancer. PMID: 19672874 Ref: Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. PMID: 19678923 Ref: A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans. PMID: 19679059 Ref: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. PMID: 19679400 Ref: A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. PMID: 19686742 Ref: Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. PMID: 19690194 Ref: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. PMID: 19690388 Ref: [Predictive biomarkers in colorectal cancer]. PMID: 19694362 Ref: Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. PMID: 19704056 Ref: [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?]. PMID: 19717258 Ref: p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. PMID: 19723919 Ref: MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. PMID: 19734844 Ref: Concordant DNA methylation in synchronous colorectal carcinomas. PMID: 19737982 Ref: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. PMID: 19738126 Ref: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. PMID: 19738166 Ref: Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. PMID: 19745699 Ref: Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability. PMID: 19761686 Ref: Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. PMID: 19783717 Ref: Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. PMID: 19787768 Ref: Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. PMID: 19789368 Ref: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. PMID: 19792050 Ref: [Metachronous metastasis from rectal adenocarcinoma to the penis--case report]. PMID: 19793691 Ref: KRAS and TP53 mutations in colorectal carcinoma. PMID: 19794264 Ref: Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. PMID: 19794270 Ref: Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. PMID: 19797612 Ref: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PMID: 19806185 Ref: A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. PMID: 19815694 Ref: Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. PMID: 19824059 Ref: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. PMID: 19825961 Ref: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. PMID: 19826350 Ref: Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer. PMID: 19829092 Ref: Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. PMID: 19832985 Ref: [Chemotherapy of colorectal cancer]. PMID: 19838655 Ref: Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. PMID: 19843849 Ref: BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. PMID: 19881948 Ref: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. PMID: 19884549 Ref: PIK3CA mutations predict local recurrences in rectal cancer patients. PMID: 19903786 Ref: Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. PMID: 19917537 Ref: [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients]. PMID: 19921572 Ref: Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. PMID: 19923311 Ref: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. PMID: 19934290 Ref: Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. PMID: 19959686 Ref: Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway. PMID: 20003375 Ref: Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. PMID: 20008849 Ref: KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PMID: 20020061 Ref: [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view]. PMID: 20034866 Ref: [Prognostic role of KRAS mutation in colorectal cancer]. PMID: 20034867 Ref: [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients]. PMID: 20034868 Ref: [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. PMID: 20034869 Ref: [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view]. PMID: 20034870 Ref: [A case of liver metastasis treated by cetuximab monotherapy with partial response]. PMID: 20037354 Ref: Autophagy: novel action of panitumumab in colon cancer. PMID: 20044619 Ref: [Validation study of KRAS mutation in colorectal cancer]. PMID: 20071308 Ref: Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. PMID: 20072938 Ref: MUTYH exon 7 and 13 mutations associated with colorectal cancer (MAP syndrome) are not commonly associated with sporadic pancreatic cancer. PMID: 20110747 Ref: The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. PMID: 20130433 Ref: The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. PMID: 20130434 Ref: Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. PMID: 20300583 Ref: [Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]. PMID: 20432670 Ref: Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. PMID: 20616903 Ref: ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer. PMID: 20856723 Ref: Evolving role of cetuximab in the treatment of colorectal cancer. PMID: 21188126 Ref: Medical treatment of advanced colorectal cancer in 2009. PMID: 21789113 Ref: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. PMID: 21789120 Ref: Pharmacogenetics: implementing personalized medicine. PMID: 22461093 Ref: Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. PMID: 29788610 |
Ref: High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. PMID: 19453520 Ref: Integration of panitumumab into the treatment of colorectal cancer. PMID: 19616446 Ref: KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. PMID: 19727962 Ref: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. PMID: 19731079 Ref: CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. PMID: 19790197 Ref: Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. PMID: 19809407 Ref: KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. PMID: 19813061 Ref: MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. PMID: 19862647 Ref: Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. PMID: 19879255 Ref: The EGFR pathway as an example for genotype: phenotype correlation in tumor genes. PMID: 19882270 Ref: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. PMID: 19908233 Ref: KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. PMID: 19913317 Ref: Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. PMID: 19935791 Ref: KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. PMID: 19936839 Ref: Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. PMID: 19937133 Ref: KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. PMID: 19952717 Ref: Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. PMID: 19954416 Ref: Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. PMID: 19955118 Ref: [Pathological diagnosis for individualized therapy of colorectal cancer]. PMID: 19957085 Ref: KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. PMID: 20007841 Ref: KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. PMID: 20007845 Ref: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. PMID: 20008640 Ref: Three DNA methylation epigenotypes in human colorectal cancer. PMID: 20028768 Ref: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. PMID: 20049644 Ref: Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. PMID: 20049837 Ref: KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. PMID: 20049979 Ref: Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. PMID: 20077021 Ref: [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. PMID: 20080456 Ref: Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. PMID: 20080688 Ref: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. PMID: 20080834 Ref: Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. PMID: 20086114 Ref: Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. PMID: 20088793 Ref: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PMID: 20098682 Ref: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. PMID: 20100961 Ref: Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. PMID: 20102720 Ref: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. PMID: 20103678 Ref: A novel E1B-55kD-deleted oncolytic adenovirus carrying mutant KRAS-regulated hdm2 transgene exerts specific antitumor efficacy on colorectal cancer cells. PMID: 20124454 Ref: Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. PMID: 20124488 Ref: Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. PMID: 20133499 Ref: Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. PMID: 20162668 Ref: Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. PMID: 20189054 Ref: Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. PMID: 20199127 Ref: PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. PMID: 20200425 Ref: A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. PMID: 20203003 Ref: Metastasis of colon cancer to the thyroid gland: a case diagnosed on fine-needle aspirate by a combined cytological, immunocytochemical, and molecular approach. PMID: 20213843 Ref: Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. PMID: 20222160 Ref: [Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests]. PMID: 20229816 Ref: Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. PMID: 20233436 Ref: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. PMID: 20233444 Ref: Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. PMID: 20234366 Ref: [Effects of K-ras gene mutation on colon cancer cell line Caco-2 metastasis by regulating E-cadherin/beta-catenin/p120 protein complex formation and RhoA protein activity]. PMID: 20236587 Ref: [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden]. PMID: 20297566 Ref: Kruppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. PMID: 20298593 Ref: The molecular pathology of cancer. PMID: 20351699 Ref: Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. PMID: 20354524 Ref: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. PMID: 20361188 Ref: The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. PMID: 20361930 Ref: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. PMID: 20363910 Ref: KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay. PMID: 20367313 Ref: KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. PMID: 20372787 Ref: Genetic and Chemical Models of Colorectal Cancer in Mice. PMID: 20376303 Ref: A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. PMID: 20378504 Ref: Oncogenic mutations as predictive factors in colorectal cancer. PMID: 20383189 Ref: Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. PMID: 20383576 Ref: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. PMID: 20385028 Ref: Predictive biomarker validation in practice: lessons from real trials. PMID: 20392785 Ref: Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. PMID: 20397915 Ref: A comparability study of 5 commercial KRAS tests. PMID: 20398393 Ref: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. PMID: 20399983 Ref: Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. PMID: 20406173 Ref: Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. PMID: 20406951 Ref: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. PMID: 20413299 Ref: Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes. PMID: 20413678 Ref: Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition. PMID: 20413844 Ref: KRAS testing and its importance in colorectal cancer. PMID: 20425075 Ref: Recent patents and advances in genomic biomarker discovery for colorectal cancers. PMID: 20426761 Ref: Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. PMID: 20431028 Ref: Calcium, vitamin D, VDR genotypes, and epigenetic and genetic changes in rectal tumors. PMID: 20432164 Ref: Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? PMID: 20444249 Ref: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. PMID: 20454511 Ref: Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. PMID: 20459770 Ref: MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. PMID: 20461754 Ref: Integration of multiple signaling pathway activities resolves K-RAS/N-RAS mutation paradox in colon epithelial cell response to inflammatory cytokine stimulation. PMID: 20473400 Ref: A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. PMID: 20482381 Ref: Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. PMID: 20492682 Ref: Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. PMID: 20494973 Ref: [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials]. PMID: 20495306 Ref: [The anti EGFR antibody indication between the Japanese and overseas guidelines]. PMID: 20495310 Ref: BRAF mutations in sporadic colorectal carcinoma from polish patients. PMID: 20496269 Ref: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. PMID: 20501503 Ref: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. PMID: 20507599 Ref: Molecular markers in the treatment of metastatic colorectal cancer. PMID: 20526105 Ref: Nuclear beta-catenin expression and Wnt signalling: in defence of the dogma. PMID: 20527017 Ref: Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. PMID: 20530704 Ref: Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PMID: 20532039 Ref: [Antibody therapy in cancer]. PMID: 20535960 Ref: Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? PMID: 20550522 Ref: Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. PMID: 20562906 Ref: Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. PMID: 20563247 Ref: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. PMID: 20565773 Ref: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. PMID: 20570890 Ref: Comparison of two different screening methods for the KRAS mutation in colorectal cancer. PMID: 20575464 Ref: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. PMID: 20583607 Ref: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. PMID: 20584808 Ref: Therapeutic modulation of k-ras signaling in colorectal cancer. PMID: 20594936 Ref: T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. PMID: 20616015 Ref: The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. PMID: 20616366 Ref: Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. PMID: 20622004 Ref: Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. PMID: 20627194 Ref: Alcohol consumption and rectal tumor mutations and epigenetic changes. PMID: 20628283 Ref: Integrating biomarkers into clinical decision making for colorectal cancer. PMID: 20630847 Ref: Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer. PMID: 20630850 Ref: Targeted therapy in advanced colorectal cancer: more data, more questions. PMID: 20631611 Ref: [Recent developments of pharmacogenomics in the treatment of colorectal cancers]. PMID: 20637356 Ref: MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. PMID: 20640893 Ref: [Significance of K-ras detection in colorectal cancer]. PMID: 20646601 Ref: Progress in cancer chemotherapy with special stress on molecular-targeted therapy. PMID: 20651047 Ref: KRAS and BRAF mutation analysis from liquid-based cytology brushings of colorectal carcinoma in comparison with formalin-fixed, paraffin-embedded tissue. PMID: 20651341 Ref: Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. PMID: 20652941 Ref: The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. PMID: 20652953 Ref: Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. PMID: 20655395 Ref: Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. PMID: 20673328 Ref: KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. PMID: 20680106 Ref: Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. PMID: 20682317 Ref: Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. PMID: 20682398 Ref: Epigenetic inactivation of tumor suppressor SFRP2 and point mutation in KRAS proto-oncogene in fistula-associated mucinous type anal adenocarcinoma: report of two cases. PMID: 20686305 Ref: Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers. PMID: 20696052 Ref: Modification and implementation of NCCN guidelines on colon cancer in the Middle East and North Africa region. PMID: 20697127 Ref: Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. PMID: 20701442 Ref: Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. PMID: 20703819 Ref: Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. PMID: 20708155 Ref: Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. PMID: 20712532 Ref: Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. PMID: 20713879 Ref: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. PMID: 20718705 Ref: Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. PMID: 20718710 Ref: Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. PMID: 20725992 Ref: High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles. PMID: 20732413 Ref: BRAF testing in advanced colorectal cancer: is it ready for prime time? PMID: 20733556 Ref: A miniaturized spatial temperature gradient capillary electrophoresis system with radiative heating and automated sample introduction for DNA mutation detection. PMID: 20734373 Ref: NRAS mutations are rare in colorectal cancer. PMID: 20736745 Ref: Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma - A Report of Two Cases. PMID: 20740189 Ref: Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. PMID: 20808308 Ref: Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. PMID: 20823162 Ref: [mRNA quantification. The next challenge in routine diagnostics]. PMID: 20824431 Ref: Circulating free tumor DNA and colorectal cancer. PMID: 20832215 Ref: Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. PMID: 20833970 Ref: American Society of Clinical Oncology 2010 colorectal update. PMID: 20836671 Ref: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. PMID: 20842128 Ref: Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. PMID: 20848649 Ref: Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. PMID: 20855834 Ref: EGFR and KRAS in colorectal cancer. PMID: 20857619 Ref: A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. PMID: 20864632 Ref: KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PMID: 20877448 Ref: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? PMID: 20921461 Ref: MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. PMID: 20924129 Ref: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. PMID: 20927778 Ref: Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. PMID: 20932136 Ref: Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. PMID: 20935157 Ref: Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. PMID: 20939116 Ref: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. PMID: 20942929 Ref: What can the molecular pathologist offer for optimal decision making? PMID: 20943604 Ref: Targeted therapeutic agents for colorectal cancer. PMID: 20951919 Ref: KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. PMID: 20959826 Ref: SEOM clinical guidelines for the treatment of advanced colorectal cancer. PMID: 20974564 Ref: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. PMID: 20978259 Ref: Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. PMID: 20979647 Ref: Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). PMID: 21036743 Ref: Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. PMID: 21036746 Ref: Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. PMID: 21037082 Ref: High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples. PMID: 21052001 Ref: Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. PMID: 21053280 Ref: [Colorectal serrated lesions: current insight on their role in colorectal carcinogenesis]. PMID: 21053517 Ref: [K-ras gene mutation in colorectal cancer and its clinicopathologic significance]. PMID: 21055216 Ref: Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. PMID: 21073737 Ref: [Two cases of colorectal cancer patients with poor performance status who had unresectable liver metastasis effectively treated by cetuximab]. PMID: 21084825 Ref: DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PMID: 21103049 Ref: Kras in metastatic colorectal cancer. PMID: 21104470 Ref: COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma. PMID: 21110880 Ref: KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. PMID: 21122130 Ref: Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer. PMID: 21127395 Ref: Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? PMID: 21129611 Ref: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. PMID: 21139621 Ref: Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. PMID: 21151408 Ref: Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. PMID: 21155011 Ref: Population-based epidemiology, risk factors and screening of intraductal papillary mucinous neoplasm patients. PMID: 21160836 Ref: Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. PMID: 21161938 Ref: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. PMID: 21163770 Ref: Chemotherapy of metastatic colorectal cancer. PMID: 21180382 Ref: KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. PMID: 21187522 Ref: Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. PMID: 21197450 Ref: [Targeted therapies in colorectal cancer]. PMID: 21197741 Ref: Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. PMID: 21208840 Ref: [Screening for K-ras mutations in colorectal and lung cancers by using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing]. PMID: 21215167 Ref: [Clinical significance of BRAF mutations in colorectal cancer]. PMID: 21220223 Ref: Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. PMID: 21275455 Ref: Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. PMID: 21299161 Ref: Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. PMID: 21474966 Ref: Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review. PMID: 21478103 Ref: LNA-based PCR clamping enrichment assay for the identification of KRAS mutations. PMID: 21896996 Ref: KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography. PMID: 22072121 Ref: KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy. PMID: 22811812 Ref: KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. PMID: 23074403 Ref: PMID: 26065050 |
Ref: Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. PMID: 20473920 Ref: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. PMID: 20563851 Ref: PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. PMID: 20571907 Ref: KRAS testing on colo-rectal carcinoma cytological imprints. PMID: 20607679 Ref: Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. PMID: 20635392 Ref: Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. PMID: 20645028 Ref: Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers. PMID: 20696815 Ref: All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. PMID: 20817364 Ref: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. PMID: 20824716 Ref: Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. PMID: 20848094 Ref: Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. PMID: 20888703 Ref: The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. PMID: 20926413 Ref: Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. PMID: 20949557 Ref: Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. PMID: 20956938 Ref: Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX. PMID: 20972872 Ref: KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. PMID: 21029218 Ref: Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. PMID: 21030527 Ref: Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. PMID: 21031422 Ref: Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. PMID: 21035469 Ref: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. PMID: 21036793 Ref: Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-beta-signaling pathway. PMID: 21088106 Ref: Molecular genetics of colorectal cancer. PMID: 21090969 Ref: Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. PMID: 21099348 Ref: Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. PMID: 21104178 Ref: Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing. PMID: 21113056 Ref: Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. PMID: 21115601 Ref: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. PMID: 21118963 Ref: MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. PMID: 21140203 Ref: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. PMID: 21148749 Ref: Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. PMID: 21159060 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. PMID: 21174064 Ref: Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. PMID: 21190026 Ref: Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. PMID: 21193546 Ref: Activation and involvement of Ral GTPases in colorectal cancer. PMID: 21199803 Ref: Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. PMID: 21200037 Ref: MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. PMID: 21213373 Ref: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. PMID: 21216929 Ref: Genetics: In colorectal cancer, not all KRAS mutations are created equal. PMID: 21218523 Ref: Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. PMID: 21227396 Ref: KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. PMID: 21228365 Ref: Downregulation of the hedgehog receptor PTCH1 in colorectal serrated adenocarcinomas is not caused by PTCH1 mutations. PMID: 21234763 Ref: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. PMID: 21239505 Ref: Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis. PMID: 21242956 Ref: The American College of Gastroenterology Emily Couric Lecture--the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? PMID: 21266962 Ref: A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. PMID: 21273607 Ref: The Evi1, microRNA-143, K-Ras axis in colon cancer. PMID: 21276449 Ref: Targeted biotherapy in metastatic colorectal carcinoma: Current practice. PMID: 21277276 Ref: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PMID: 21283802 Ref: Novel modalities in the treatment of patients with KRAS-mutated colorectal cancer. PMID: 21285867 Ref: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. PMID: 21285991 Ref: Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. PMID: 21286919 Ref: BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer. PMID: 21289333 Ref: Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. PMID: 21300933 Ref: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. PMID: 21305640 Ref: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. PMID: 21310826 Ref: A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. PMID: 21315413 Ref: Polyamine transport systems in mammalian cells and tissues. PMID: 21318884 Ref: High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. PMID: 21319808 Ref: Implementing prognostic and predictive biomarkers in CRC clinical trials. PMID: 21321566 Ref: Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. PMID: 21327931 Ref: Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. PMID: 21336262 Ref: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. PMID: 21340604 Ref: Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. PMID: 21347779 Ref: SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. PMID: 21354055 Ref: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. PMID: 21356164 Ref: KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. PMID: 21364579 Ref: Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. PMID: 21371307 Ref: Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. PMID: 21380628 Ref: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. PMID: 21383284 Ref: Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. PMID: 21390154 Ref: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. PMID: 21398618 Ref: In vivo fluorescence-based endoscopic detection of colon dysplasia in the mouse using a novel peptide probe. PMID: 21408169 Ref: Is there any association between TACSTD2, KIAA1253, Ku70 and mutant KRAS gene expression and clinical-pathological features of colorectal cancer? PMID: 21423092 Ref: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. PMID: 21423154 Ref: KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. PMID: 21424126 Ref: Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. PMID: 21425139 Ref: Molecular predictors of response to chemotherapy in colorectal cancer. PMID: 21427555 Ref: Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations. PMID: 21436632 Ref: Impact of KRAS Mutations on Management of Colorectal Carcinoma. PMID: 21437184 Ref: External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. PMID: 21441573 Ref: Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. PMID: 21447798 Ref: Targeted therapies: dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab. PMID: 21451492 Ref: High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. PMID: 21455633 Ref: Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. PMID: 21462086 Ref: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. PMID: 21464044 Ref: Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. PMID: 21468686 Ref: Variation in the CYP19A1 gene and risk of colon and rectal cancer. PMID: 21479914 Ref: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. PMID: 21483104 Ref: Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. PMID: 21508389 Ref: DNA methylation predicts recurrence from resected stage III proximal colon cancer. PMID: 21509761 Ref: Amphiregulin exosomes increase cancer cell invasion. PMID: 21514161 Ref: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. PMID: 21516079 Ref: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. PMID: 21521850 Ref: Molecular diagnostics of colorectal cancer. PMID: 21526956 Ref: Detection of tumor DNA at the margins of colorectal cancer liver metastasis. PMID: 21531819 Ref: Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases. PMID: 21536390 Ref: Candidate pathway polymorphisms in one-carbon metabolism and risk of rectal tumor mutations. PMID: 21537397 Ref: Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. PMID: 21553007 Ref: Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. PMID: 21554739 Ref: Cetuximab in the treatment of patients with colorectal cancer. PMID: 21557708 Ref: Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. PMID: 21558395 Ref: KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. PMID: 21575616 Ref: Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. PMID: 21603900 Ref: Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. PMID: 21609938 Ref: Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. PMID: 21618350 Ref: Stromal cells do not share KRAS mutations that the epithelial component harbors in colorectal carcinomas. PMID: 21624768 Ref: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. PMID: 21632860 Ref: Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. PMID: 21635994 Ref: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. PMID: 21641636 Ref: Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer. PMID: 21646605 Ref: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. PMID: 21646616 Ref: [Effect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer]. PMID: 21655475 Ref: Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. PMID: 21660972 Ref: Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? PMID: 21661405 Ref: Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation. PMID: 21665177 Ref: Inhibition of miR-193a expression by Max and RXRalpha activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. PMID: 21670079 Ref: The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. PMID: 21671463 Ref: EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. PMID: 21673069 Ref: Molecular alterations associated with liver metastases development in colorectal cancer patients. PMID: 21673680 Ref: A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P PMID: 21674991 Ref: [Identification of K-RAS mutations in colorectal cancer patients in Israel]. PMID: 21678640 Ref: [Personalized medicine--the future is already here]. PMID: 21678641 Ref: Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). PMID: 21679003 Ref: Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. PMID: 21680706 Ref: KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. PMID: 21686179 Ref: EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. PMID: 21694725 Ref: Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PMID: 21698197 Ref: Comparison of KRAS mutation tests in colorectal cancer patients. PMID: 21699410 Ref: Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. PMID: 21699772 Ref: Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. PMID: 21701884 Ref: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. PMID: 21704278 Ref: Do all lung adenocarcinomas follow a stepwise progression? PMID: 21705107 Ref: Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. PMID: 21725213 Ref: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? PMID: 21729677 Ref: Development of molecular biomarkers in individualized treatment of colorectal cancer. PMID: 21729679 Ref: KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. PMID: 21737577 Ref: Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models. PMID: 21737635 Ref: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PMID: 21738740 Ref: Differential detection of KRAS mutations in codons 12 and 13 with a modified loop-hybrid (LH) mobility shift assay using an insert-type LH-generator. PMID: 21741959 Ref: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. PMID: 21742964 Ref: VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. PMID: 21743435 Ref: Laboratory methods for KRAS mutation analysis. PMID: 21745016 Ref: [KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma]. PMID: 21751504 Ref: [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. PMID: 21772090 Ref: FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. PMID: 21772113 Ref: Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. PMID: 21775746 Ref: Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. PMID: 21785539 Ref: Predictive molecular classifiers in colorectal cancer. PMID: 21810517 Ref: [KRAS mutation test]. PMID: 21815483 Ref: Cancer immunology--analysis of host and tumor factors for personalized medicine. PMID: 21826083 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? PMID: 21836482 Ref: Familial colorectal cancer type X syndrome: two distinct molecular entities? PMID: 21837511 Ref: Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. PMID: 21837660 Ref: Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. PMID: 21849660 Ref: APC and KRAS mutations in distal colorectal polyps are related to smoking habits in men: results of a cross-sectional study. PMID: 21865138 Ref: Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. PMID: 21865946 Ref: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. PMID: 21868546 Ref: Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. PMID: 21873159 Ref: KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. PMID: 21873171 Ref: Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. PMID: 21874108 Ref: EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. PMID: 21880790 Ref: Multiple intratumoral KRAS mutations can clonally segregate to different lymph node metastases in colon cancer. PMID: 21884216 Ref: Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. PMID: 21884745 Ref: KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. PMID: 21894049 Ref: Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. PMID: 21900113 Ref: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. PMID: 21900593 Ref: Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PMID: 21901162 Ref: Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome. PMID: 21909432 Ref: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. PMID: 21910869 Ref: [A case of sigmoid colon cancer with liver and ovarian metastases effectively treated by panitumumab after acquiring resistance to prior chemotherapy regimens]. PMID: 21918357 Ref: Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. PMID: 21931273 Ref: Aloe vera non-decolorized whole leaf extract-induced large intestinal tumors in F344 rats share similar molecular pathways with human sporadic colorectal tumors. PMID: 21937742 Ref: [Tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect KRAS and BRAF mutations]. PMID: 21942085 Ref: BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. PMID: 21943101 Ref: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. PMID: 21943394 Ref: TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PMID: 21949851 Ref: Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens. PMID: 21968808 Ref: Multidisciplinary approach of colorectal liver metastases. PMID: 21975333 Ref: Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. PMID: 21985784 Ref: A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. PMID: 21994416 Ref: Anti-EGFR therapy in first-line colorectal cancer. PMID: 21999123 Ref: Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. PMID: 22014273 Ref: Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. PMID: 22016105 Ref: Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension. PMID: 22022941 Ref: Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. PMID: 22028619 Ref: Biomarker use in colorectal cancer therapy. PMID: 22056657 Ref: Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. PMID: 22070922 Ref: KRAS detection in colonic tumors by DNA extraction from FTA paper: the molecular touch-prep. PMID: 22089345 Ref: Expression of p16INK4a, alone or combined with p53, is predictive of better prognosis in colorectal adenocarcinoma in Tunisian patients. PMID: 22095233 Ref: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. PMID: 22117530 Ref: KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries. PMID: 22139644 Ref: [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]. PMID: 22145213 Ref: Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. PMID: 22147978 Ref: Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis. PMID: 22180717 Ref: Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. PMID: 22199994 Ref: KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PMID: 22216189 Ref: Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients. PMID: 22248908 Ref: Digital pathology in personalized cancer therapy. PMID: 22252751 Ref: Concurrent mutation in exons 1 and 2 of the K-ras oncogene in colorectal cancer. PMID: 22252770 Ref: [The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response]. PMID: 22257237 Ref: [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy]. PMID: 22329297 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 Ref: Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. PMID: 22977561 Ref: Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients. PMID: 23357879 Ref: Predictive and prognostic factors in colorectal cancer: a personalized approach. PMID: 24212777 Ref: Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice. PMID: 24212785 Ref: Review of histopathological and molecular prognostic features in colorectal cancer. PMID: 24212832 Ref: The role of kras mutations and MSI status in diagnosis of colorectal cancer. PMID: 24834160 Ref: Biotherapy in the Adjuvant Treatment of Colorectal Cancer. PMID: 27942334 |
Ref: Review of biomarkers in colorectal cancer. PMID: 21040359 Ref: Genetic variation in bone morphogenetic protein and colon and rectal cancer. PMID: 21387313 Ref: Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. PMID: 21445971 Ref: Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. PMID: 21652149 Ref: Genome-scale analysis of aberrant DNA methylation in colorectal cancer. PMID: 21659424 Ref: Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. PMID: 21706149 Ref: Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. PMID: 21768877 Ref: Rhabdoid carcinoma of the colon: a distinct entity with a very aggressive behavior: a case report associated with a polyposis coli and review of the literature. PMID: 21791485 Ref: Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. PMID: 21830278 Ref: The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines. PMID: 21879255 Ref: Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. PMID: 21913035 Ref: MicroRNA profiling differentiates colorectal cancer according to KRAS status. PMID: 21922590 Ref: Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. PMID: 21925954 Ref: Oncogenic PIK3CA mutations in colorectal cancers and polyps. PMID: 21932420 Ref: Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. PMID: 21971641 Ref: Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. PMID: 21984339 Ref: CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. PMID: 22001634 Ref: Assessment of three epigenotypes in colorectal cancer by combined bisulfite restriction analysis. PMID: 22006538 Ref: The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. PMID: 22019796 Ref: Novel approach to abuse the hyperactive K-Ras pathway for adenoviral gene therapy of colorectal cancer. PMID: 22020090 Ref: Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. PMID: 22038927 Ref: PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. PMID: 22039088 Ref: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? PMID: 22043994 Ref: Role of ancillary studies in fine-needle aspiration from selected tumors. PMID: 22045615 Ref: Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing. PMID: 22048888 Ref: Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. PMID: 22055112 Ref: Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. PMID: 22062357 Ref: Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. PMID: 22068457 Ref: Two initiation sites of early detection of colon cancer, revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of tumor cells. PMID: 22108866 Ref: Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. PMID: 22112971 Ref: Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. PMID: 22114137 Ref: Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. PMID: 22115708 Ref: Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. PMID: 22118887 Ref: Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. PMID: 22120473 Ref: Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. PMID: 22126621 Ref: Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. PMID: 22130903 Ref: Carnosine inhibits KRAS-mediated HCT116 proliferation by affecting ATP and ROS production. PMID: 22137144 Ref: Is KRAS mutation associated with interval colorectal cancers? PMID: 22138963 Ref: The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. PMID: 22154651 Ref: No evidence for PML-RARa bcr1 fusion gene in colorectal cancer. PMID: 22167334 Ref: To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. PMID: 22169039 Ref: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. PMID: 22169769 Ref: Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. PMID: 22173329 Ref: Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. PMID: 22173548 Ref: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. PMID: 22173549 Ref: TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. PMID: 22188812 Ref: Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. PMID: 22189054 Ref: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. PMID: 22189472 Ref: KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. PMID: 22189714 Ref: COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. PMID: 22194627 Ref: The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. PMID: 22198706 Ref: Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. PMID: 22208484 Ref: Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. PMID: 22210086 Ref: Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. PMID: 22210091 Ref: Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. PMID: 22223432 Ref: Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. PMID: 22228162 Ref: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. PMID: 22228631 Ref: Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. PMID: 22229245 Ref: Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. PMID: 22229849 Ref: A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. PMID: 22233696 Ref: Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. PMID: 22245873 Ref: Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. PMID: 22247021 Ref: Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer. PMID: 22252179 Ref: Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. PMID: 22260668 Ref: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. PMID: 22261800 Ref: Emerging role of cetuximab in the treatment of colorectal cancer. PMID: 22264223 Ref: Search for novel target molecules for the effective treatment or prevention of colorectal cancer. PMID: 22269287 Ref: Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. PMID: 22270257 Ref: Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. PMID: 22272560 Ref: KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. PMID: 22282307 Ref: Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. PMID: 22282467 Ref: PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. PMID: 22285706 Ref: Personalized treatment of colorectal cancer. PMID: 22286587 Ref: Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. PMID: 22287190 Ref: Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. PMID: 22306670 Ref: KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. PMID: 22306671 Ref: BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. PMID: 22314188 Ref: Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. PMID: 22318865 Ref: Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. PMID: 22321154 Ref: NF-kappaB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IkappaBalpha pathway. PMID: 22327383 Ref: [Pathologically complete response for unresectable stage IV rectal cancer using systemic chemotherapy with panitumumab - a case report]. PMID: 22333651 Ref: Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. PMID: 22337533 Ref: TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. PMID: 22341439 Ref: Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. PMID: 22349355 Ref: Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. PMID: 22357840 Ref: The times have changed: molecular pathology is here to stay. A commentary on: analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Le PMID: 22358180 Ref: First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. PMID: 22363067 Ref: KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. PMID: 22369372 Ref: Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines. PMID: 22383492 Ref: Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. PMID: 22385512 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. PMID: 22393095 Ref: Molecular alterations in colitis-associated colorectal neoplasia: study from a low prevalence area using magnifying chromo colonoscopy. PMID: 22398042 Ref: Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. PMID: 22409860 Ref: Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. PMID: 22412142 Ref: Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. PMID: 22414609 Ref: Therapeutic strategy in unresectable metastatic colorectal cancer. PMID: 22423266 Ref: Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. PMID: 22427190 Ref: Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. PMID: 22427198 Ref: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. PMID: 22427238 Ref: Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. PMID: 22430888 Ref: Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. PMID: 22444159 Ref: Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. PMID: 22446020 Ref: Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. PMID: 22451720 Ref: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. PMID: 22452538 Ref: KRAS mutational status of endoscopic biopsies matches resection specimens. PMID: 22461648 Ref: Three different KRAS statuses in three synchronous colorectal cancers. PMID: 22467075 Ref: Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). PMID: 22473163 Ref: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. PMID: 22474202 Ref: Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. PMID: 22481281 Ref: Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. PMID: 22489692 Ref: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. PMID: 22490361 Ref: Comparison of the chemosensitivity of the primary lesion and a pancreatic metastasis of colon cancer: a case report. PMID: 22493386 Ref: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. PMID: 22496204 Ref: Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPbeta-dependent suppression of EGFR expression. PMID: 22496619 Ref: Use of multiple biomarkers for the localization and characterization of colon cancer stem cells by indirect immunocytochemistry. PMID: 22504585 Ref: Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. PMID: 22508672 Ref: Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. PMID: 22510757 Ref: Panitumumab: a summary of clinical development in colorectal cancer and future directions. PMID: 22515440 Ref: A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. PMID: 22515520 Ref: Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. PMID: 22517696 Ref: KRAS mutation and NF-kappaB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer. PMID: 22526587 Ref: Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. PMID: 22549179 Ref: Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. PMID: 22552366 Ref: Applicability of a System for fully automated nucleic acid extraction from formalin-fixed paraffin-embedded sections for routine KRAS mutation testing. PMID: 22555094 Ref: Genetic alterations in colorectal cancer. PMID: 22574233 Ref: Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. PMID: 22579930 Ref: Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. PMID: 22581265 Ref: K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. PMID: 22583358 Ref: High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. PMID: 22584434 Ref: KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PMID: 22586484 Ref: Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. PMID: 22593440 Ref: The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. PMID: 22594497 Ref: Hypericum androsaemum water extract inhibits proliferation in human colorectal cancer cells through effects on MAP kinases and PI3K/Akt pathway. PMID: 22596086 Ref: High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms. PMID: 22609129 Ref: Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. PMID: 22610356 Ref: Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. PMID: 22613949 Ref: Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. PMID: 22618722 Ref: [Biomarker for colorectal cancer]. PMID: 22620004 Ref: Alterations of the base excision repair gene MUTYH in sporadic colorectal cancer. PMID: 22641385 Ref: KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. PMID: 22641662 Ref: ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. PMID: 22641666 Ref: [Comparison of different methods of molecular-genetic analysis of somatic mutations in K-ras gene in patients with colorectal cancer]. PMID: 22642176 Ref: A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. PMID: 22643351 Ref: Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer. PMID: 22655257 Ref: Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. PMID: 22660396 Ref: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. PMID: 22665543 Ref: Missense mutations in MLH1, MSH2, KRAS, and APC genes in colorectal cancer patients in Malaysia. PMID: 22669205 Ref: Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. PMID: 22674635 Ref: KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PMID: 22675430 Ref: Histological and molecular evaluation of patient-derived colorectal cancer explants. PMID: 22675560 Ref: Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. PMID: 22690082 Ref: Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. PMID: 22696593 Ref: [Age-related and clinical-pathogenetic features of colorectal cancer associated with status of K-ras gene]. PMID: 22708448 Ref: Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. PMID: 22712795 Ref: A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. PMID: 22713664 Ref: KRAS mutant colorectal tumors: past and present. PMID: 22714415 Ref: Digital detection of multiple minority mutants in stool DNA for noninvasive colorectal cancer diagnosis. PMID: 22715805 Ref: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. PMID: 22722830 Ref: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. PMID: 22723336 Ref: Characteristics of advanced- and non advanced sporadic polypoid colorectal adenomas: correlation to KRAS mutations. PMID: 22729813 Ref: Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers? PMID: 22735932 Ref: Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation. PMID: 22740893 Ref: PIK3CA mutation and methylation influences the outcome of colorectal cancer. PMID: 22740953 Ref: Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. PMID: 22740969 Ref: Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. PMID: 22745110 Ref: Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients. PMID: 22752373 Ref: Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the betaGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo. PMID: 22752425 Ref: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. PMID: 22753589 Ref: A significant role of lipogenic enzymes in colorectal cancer. PMID: 22753716 Ref: Domain landscapes of somatic mutations in cancer. PMID: 22759657 Ref: A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. PMID: 22773565 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab]. PMID: 22790058 Ref: Differential involvement of RalA and RalB in colorectal cancer. PMID: 22790202 Ref: CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. PMID: 22792460 Ref: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. PMID: 22797671 Ref: Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation. PMID: 22800643 Ref: Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies. PMID: 22802884 Ref: The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. PMID: 22803799 Ref: KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. PMID: 22804747 Ref: Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. PMID: 22804917 Ref: KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. PMID: 22805329 Ref: Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PMID: 22808230 Ref: Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. PMID: 22810479 Ref: Comprehensive molecular characterization of human colon and rectal cancer. PMID: 22810696 Ref: BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PMID: 22815993 Ref: Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. PMID: 22825584 Ref: K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. PMID: 22826122 Ref: Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. PMID: 22828149 Ref: Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. PMID: 22830422 Ref: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. PMID: 22840368 Ref: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. PMID: 22845480 Ref: Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. PMID: 22846108 Ref: Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). PMID: 22855150 Ref: [Therapeutic monoclonal antibodies in oncology]. PMID: 22863361 Ref: Study of KRAS new predictive marker in a clinical laboratory. PMID: 22865324 Ref: The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. PMID: 22869096 Ref: Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. PMID: 22872705 Ref: Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. PMID: 22876814 Ref: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. PMID: 22876876 Ref: The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. PMID: 22882224 Ref: Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. PMID: 22898351 Ref: [Evaluation of skin toxicity caused by cetuximab related to its clinical response]. PMID: 22902446 Ref: [A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI]. PMID: 22902456 Ref: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. PMID: 22909976 Ref: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PMID: 22911782 Ref: The prognostic value of KRAS mutations in patients with colorectal cancer. PMID: 22922794 Ref: Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. PMID: 22925370 Ref: Digital pathology in personalized cancer therapy. PMID: 22925795 Ref: Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors. PMID: 22927297 Ref: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. PMID: 22931052 Ref: High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. PMID: 22938585 Ref: Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo. PMID: 22964484 Ref: Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. PMID: 22969927 Ref: Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. PMID: 22971512 Ref: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. PMID: 22975375 Ref: What can molecular pathology offer for optimal decision making? PMID: 22987994 Ref: Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. PMID: 22995252 Ref: beta-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients. PMID: 23009572 Ref: Comment on 'a comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens'. PMID: 23011482 Ref: Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. PMID: 23017669 Ref: KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. PMID: 23027075 Ref: MAP kinase genes and colon and rectal cancer. PMID: 23027623 Ref: Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study. PMID: 23028236 Ref: Activating mutations in beta-catenin in colon cancer cells alter their interaction with macrophages; the role of snail. PMID: 23029025 Ref: KRAS and BRAF mutations in Serbian patients with colorectal cancer. PMID: 23033302 Ref: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. PMID: 23045248 Ref: Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. PMID: 23045412 Ref: A LIN28B polymorphism predicts for colon cancer survival. PMID: 23052130 Ref: Meeting the biologic challenge of colorectal metastases. PMID: 23053740 Ref: Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. PMID: 23055745 Ref: FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis. PMID: 23060561 Ref: Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan((R)) -MGB probe genotyping method. PMID: 23060932 Ref: Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study. PMID: 23061900 Ref: Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines. PMID: 23063521 Ref: [Two cases of metastatic colorectal cancer in wild-type K-RAS effectively treated by panitumumab]. PMID: 23064074 Ref: KRAS mutation testing in metastatic colorectal cancer. PMID: 23066310 Ref: Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. PMID: 23071293 Ref: Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. PMID: 23075074 Ref: Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. PMID: 23077464 Ref: Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer. PMID: 23091721 Ref: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. PMID: 23094721 Ref: Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. PMID: 23095620 Ref: [The change of pathology in the era of personalized medicine using the example of discordant KRAS mutational status in metastasized colorectal carcinoma]. PMID: 23111797 Ref: MUC5AC/beta-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors. PMID: 23112547 Ref: Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. PMID: 23114745 Ref: Prognostic and predictive factors in colorectal cancer. PMID: 23116828 Ref: Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. PMID: 23125007 Ref: Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PMID: 23144978 Ref: Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. PMID: 23150730 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 Ref: Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer. PMID: 23152928 Ref: [K-ras mutational status and tumour-infiltrating lymphocytes in human colon cancer: state of the art and future perspectives]. PMID: 23153426 Ref: Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. PMID: 23154512 Ref: [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases]. PMID: 23157823 Ref: [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese]. PMID: 23157824 Ref: [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. PMID: 23157825 Ref: [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]. PMID: 23157826 Ref: [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas]. PMID: 23157827 Ref: [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma]. PMID: 23157828 Ref: [Consensus for KRAS gene mutation detection in colorectal carcinoma]. PMID: 23157836 Ref: KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. PMID: 23161231 Ref: Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. PMID: 23167843 Ref: Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. PMID: 23171437 Ref: The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. PMID: 23173124 Ref: Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer. PMID: 23173730 Ref: Prognostic and predictive roles of KRAS mutation in colorectal cancer. PMID: 23202889 Ref: KRAS mutations and subtyping in colorectal cancer in Jordanian patients. PMID: 23205087 Ref: Circulating tumor cells in lung cancer. PMID: 23207444 Ref: KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PMID: 23209813 Ref: Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PMID: 23213241 Ref: Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PMID: 23226389 Ref: No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. PMID: 23226426 Ref: Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. PMID: 23226727 Ref: Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. PMID: 23227266 Ref: Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. PMID: 23236152 Ref: [Anti-EGFR antibody therapy for colorectal cancer]. PMID: 23259389 Ref: KRAS Testing: A Tool for the Implementation of Personalized Medicine. PMID: 23264846 Ref: Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PMID: 23284732 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 Ref: [Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine]. PMID: 23323463 Ref: High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. PMID: 23335937 Ref: Colorectal carcinoma under microscopy: patohistology or much more? PMID: 23373356 Ref: [A study on the mutation of P53 and K-ras gene in colorectal adenomas and colorectal carcinomas]. PMID: 23387205 Ref: ABO and Rh blood groups and risk of colorectal adenocarcinoma. PMID: 23464411 Ref: Acrometastasis as the Initial Presentation of a KRAS-Positive Colon Cancer. PMID: 23525126 Ref: [Competing endogenous RNA regulation mechanism and its role in the development and progression of colorectal cancer]. PMID: 23596669 Ref: Molecular profile of colorectal cancer in Indonesia: is there another pathway? PMID: 24834203 |
Ref: Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. PMID: 22270106 Ref: Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. PMID: 22430215 Ref: Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. PMID: 22441881 Ref: Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. PMID: 22458846 Ref: Tumor markers in clinical practice: a review focusing on common solid cancers. PMID: 22584792 Ref: Development of a computerized morphometry application for assessment of the tumor fraction in colon carcinoma tissue samples. PMID: 22595946 Ref: Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. PMID: 22615057 Ref: Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. PMID: 22638623 Ref: Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu PMID: 22644776 Ref: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. PMID: 22647972 Ref: KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. PMID: 22672749 Ref: Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. PMID: 22696308 Ref: Colorectal cancer and RASSF family--a special emphasis on RASSF1A. PMID: 22733432 Ref: RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. PMID: 22751122 Ref: Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation. PMID: 22752244 Ref: Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. PMID: 22762963 Ref: Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. PMID: 22786759 Ref: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. PMID: 22798500 Ref: Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. PMID: 22833420 Ref: Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. PMID: 22847744 Ref: MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. PMID: 22899370 Ref: Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. PMID: 22936063 Ref: The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer. PMID: 22976378 Ref: HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53. PMID: 22982087 Ref: Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. PMID: 22991232 Ref: Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. PMID: 23010994 Ref: Molecular patterns in the evolution of serrated lesion of the colorectum. PMID: 23011871 Ref: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. PMID: 23015072 Ref: Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. PMID: 23067221 Ref: Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. PMID: 23073979 Ref: RNA biomarkers in colorectal cancer. PMID: 23079397 Ref: Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. PMID: 23083634 Ref: KRAS mutations are associated with specific morphologic features in colon cancer. PMID: 23090042 Ref: The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients. PMID: 23108567 Ref: Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. PMID: 23128394 Ref: Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. PMID: 23136247 Ref: KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. PMID: 23155138 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. PMID: 23161513 Ref: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. PMID: 23165447 Ref: KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. PMID: 23175150 Ref: Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. PMID: 23188063 Ref: Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. PMID: 23199549 Ref: Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis. PMID: 23211288 Ref: Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. PMID: 23225808 Ref: Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. PMID: 23233484 Ref: The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. PMID: 23234544 Ref: KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. PMID: 23242173 Ref: Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. PMID: 23255930 Ref: Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. PMID: 23265711 Ref: Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. PMID: 23271133 Ref: KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. PMID: 23274581 Ref: Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. PMID: 23280667 Ref: Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. PMID: 23286373 Ref: The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. PMID: 23297805 Ref: Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. PMID: 23319808 Ref: Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens. PMID: 23324583 Ref: A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. PMID: 23328486 Ref: The serrated pathway to colorectal carcinoma: current concepts and challenges. PMID: 23339363 Ref: Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. PMID: 23347191 Ref: Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. PMID: 23348904 Ref: A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. PMID: 23354161 Ref: [Application of matrix assisted laser desorption ionization-time of flight-mass spectrometry in detecting K-ras gene mutation of colorectal cancer]. PMID: 23355247 Ref: Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions. PMID: 23355875 Ref: Targeted therapies in colorectal cancer-an integrative view by PPPM. PMID: 23356214 Ref: Two initiation sites of early detection of colon cancer revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of the tumor cells. PMID: 23357054 Ref: Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. PMID: 23368856 Ref: Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status. PMID: 23370766 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: Clinical subtypes and molecular characteristics of serrated polyposis syndrome. PMID: 23376323 Ref: A case of syncronised hereditery nonpoliposis colorectal tumor with different hystopathological type and k-ras gene mutation: case report. PMID: 23390480 Ref: A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. PMID: 23391248 Ref: Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. PMID: 23400451 Ref: Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. PMID: 23400679 Ref: Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. PMID: 23403635 Ref: Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. PMID: 23403822 Ref: KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. PMID: 23404247 Ref: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. PMID: 23412099 Ref: Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. PMID: 23419522 Ref: Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. PMID: 23420587 Ref: Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. PMID: 23422094 Ref: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? PMID: 23429431 Ref: EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PMID: 23441167 Ref: KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. PMID: 23455880 Ref: Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. PMID: 23456389 Ref: EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. PMID: 23459231 Ref: Development of a ligase detection reaction/CGE method using a LIF dual-channel detection system for direct identification of allelic composition of mutated DNA in a mixed population of excess wild-type DNA. PMID: 23463388 Ref: Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. PMID: 23471846 Ref: The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. PMID: 23473612 Ref: KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. PMID: 23473635 Ref: Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. PMID: 23475782 Ref: MicroRNAs in Cancer: the 22nd Hiroshima Cancer Seminar/the 4th Japanese Association for RNA Interference Joint International Symposium, 30 August 2012, Grand Prince Hotel Hiroshima. PMID: 23487440 Ref: The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. PMID: 23499205 Ref: Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. PMID: 23499207 Ref: [A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab]. PMID: 23507607 Ref: Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. PMID: 23509688 Ref: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. PMID: 23510598 Ref: KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. PMID: 23510802 Ref: KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. PMID: 23511557 Ref: KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. PMID: 23511561 Ref: Genotyping by induced Forster Resonance Energy Transfer(iFRET) mechanism and simultaneous mutation scanning. PMID: 23520118 Ref: Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PMID: 23520486 Ref: [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience]. PMID: 23528169 Ref: Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. PMID: 23528430 Ref: Novel biomarkers for the prediction of metastasis in colorectal cancer. PMID: 23530884 Ref: KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. PMID: 23531339 Ref: Significance of HPV infection and genic mutation of APC and K-ras in patients with rectal cancer. PMID: 23534709 Ref: A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer. PMID: 23536897 Ref: Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. PMID: 23538047 Ref: A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. PMID: 23539443 Ref: Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. PMID: 23547084 Ref: The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-lin PMID: 23547747 Ref: High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. PMID: 23548132 Ref: The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. PMID: 23555026 Ref: Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PMID: 23555746 Ref: Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. PMID: 23560377 Ref: Usefulness of circulating tumor cells after preliminary chemotherapy for prediction of response to further anticancer therapy in patients with initially unresectable metastatic colorectal cancer. PMID: 23564832 Ref: KRAS gene mutations are more common in colorectal villous adenomas and in situ carcinomas than in carcinomas. PMID: 23565319 Ref: Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. PMID: 23569301 Ref: Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. PMID: 23569465 Ref: Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. PMID: 23572025 Ref: Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population. PMID: 23573237 Ref: [Biomarkers in solid tumors]. PMID: 23573523 Ref: Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. PMID: 23580570 Ref: Designing transformative clinical trials in the cancer genome era. PMID: 23589555 Ref: Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. PMID: 23592171 Ref: KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. PMID: 23606169 Ref: Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing? PMID: 23613316 Ref: Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. PMID: 23613671 Ref: Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. PMID: 23617638 Ref: Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. PMID: 23632477 Ref: PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. PMID: 23633456 Ref: Personalized cancer treatment and the myth of KRAS wild-type colon tumors. PMID: 23636143 Ref: Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. PMID: 23639600 Ref: The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. PMID: 23640097 Ref: KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing. PMID: 23645765 Ref: Companion biomarkers: paving the pathway to personalized treatment for cancer. PMID: 23656699 Ref: KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. PMID: 23657052 Ref: Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? PMID: 23660586 Ref: The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. PMID: 23660947 Ref: Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. PMID: 23665275 Ref: MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. PMID: 23665971 Ref: A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PMID: 23671647 Ref: Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PMID: 23700391 Ref: Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PMID: 23700467 Ref: Right drug for the right patient: hurdles and the path forward in colorectal cancer. PMID: 23714474 Ref: Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma. PMID: 23714502 Ref: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. PMID: 23725851 Ref: Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. PMID: 23728594 Ref: KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. PMID: 23729268 Ref: Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. PMID: 23729478 Ref: Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. PMID: 23730412 Ref: Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. PMID: 23730514 Ref: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. PMID: 23741067 Ref: Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. PMID: 23743569 Ref: Alternate dosing of cetuximab for patients with metastatic colorectal cancer. PMID: 23745159 Ref: Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. PMID: 23748663 Ref: Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. PMID: 23749251 Ref: Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. PMID: 23749901 Ref: Network quantification of EGFR signaling unveils potential for targeted combination therapy. PMID: 23752269 Ref: Discordance of KRAS mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature. PMID: 23755925 Ref: Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. PMID: 23757356 Ref: Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. PMID: 23761841 Ref: Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. PMID: 23763264 Ref: Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. PMID: 23764749 Ref: Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. PMID: 23773459 Ref: Genetic reconstitution of tumorigenesis in primary intestinal cells. PMID: 23776211 Ref: PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PMID: 23785428 Ref: Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients. PMID: 23790176 Ref: FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. PMID: 23792567 Ref: Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine. PMID: 23792572 Ref: Aspirin use and risk of colorectal cancer according to BRAF mutation status. PMID: 23800934 Ref: Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. PMID: 23807779 Ref: Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other. PMID: 23810502 Ref: KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. PMID: 23828442 Ref: Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. PMID: 23832066 Ref: Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. PMID: 23836465 Ref: Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. PMID: 23838137 Ref: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. PMID: 23849768 Ref: Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature. PMID: 23859115 Ref: KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy? PMID: 23864308 Ref: Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. PMID: 23868516 Ref: Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer. PMID: 23871153 Ref: The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. PMID: 23873478 Ref: Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PMID: 23874486 Ref: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. PMID: 23876834 Ref: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. PMID: 23878352 Ref: [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue]. PMID: 23885463 Ref: [Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma]. PMID: 23885470 Ref: Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. PMID: 23895128 Ref: The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. PMID: 23898060 Ref: Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. PMID: 23900220 Ref: Microsatellite instability affecting the T17 repeats in intron 8 of HSP110, as well as five mononucleotide repeats in patients with colorectal carcinoma. PMID: 23905898 Ref: Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PMID: 23922754 Ref: O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer. PMID: 23929436 Ref: Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. PMID: 23930204 Ref: EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. PMID: 23930206 Ref: Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. PMID: 23934607 Ref: Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PMID: 23935912 Ref: TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. PMID: 23936455 Ref: Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. PMID: 23938455 Ref: Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. PMID: 23943423 Ref: 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. PMID: 23950653 Ref: Morphological change of a laterally spreading rectal tumor over a short period. PMID: 23957258 Ref: Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. PMID: 23960095 Ref: Distinct molecular features of colorectal cancer in Ghana. PMID: 23962701 Ref: Effects of hypoxanthine substitution in peptide nucleic acids targeting KRAS2 oncogenic mRNA molecules: theory and experiment. PMID: 23972113 Ref: Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. PMID: 23979710 Ref: [Consideration of therapy for colorectal cancer with synchronous unresectable liver metastasis]. PMID: 23980038 Ref: Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC. PMID: 23983135 Ref: Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. PMID: 23983431 Ref: [A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab]. PMID: 23986063 Ref: Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. PMID: 23992303 Ref: The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. PMID: 23997939 Ref: Integrating anti-EGFR therapies in metastatic colorectal cancer. PMID: 23997940 Ref: Markers of resistance to anti-EGFR therapy in colorectal cancer. PMID: 23997942 Ref: K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. PMID: 23999847 Ref: [Colorectal cancer - personalized, stage-adjusted tumour therapy]. PMID: 24002881 Ref: Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the Adenomatous polyposis coli gene. PMID: 24005794 Ref: Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. PMID: 24006859 Ref: Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. PMID: 24012456 Ref: Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. PMID: 24019539 Ref: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. PMID: 24020794 Ref: Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. PMID: 24023327 Ref: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. PMID: 24024839 Ref: Multi-kinase modulation for colon cancer therapy. PMID: 24025253 Ref: Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. PMID: 24025413 Ref: The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. PMID: 24025416 Ref: Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification. PMID: 24038839 Ref: Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. PMID: 24042191 Ref: Epigenetic and genetic features of 24 colon cancer cell lines. PMID: 24042735 Ref: Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. PMID: 24046806 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24050544 Ref: The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. PMID: 24050852 Ref: Epidermal growth factor receptor: pathway, therapies, and pipeline. PMID: 24054705 Ref: [Determination of K-ras gene mutation in colorectal cancer tissue by capillary electrophoresis]. PMID: 24063200 Ref: K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and PCR-RFLP. PMID: 24068405 Ref: Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. PMID: 24073892 Ref: KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability. PMID: 24078161 Ref: The enigmatic ERH protein: its role in cell cycle, RNA splicing and cancer. PMID: 24078386 Ref: Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. PMID: 24085553 Ref: Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. PMID: 24086949 Ref: Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. PMID: 24092809 Ref: Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). PMID: 24102083 Ref: Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. PMID: 24104864 Ref: Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. PMID: 24105075 Ref: BRAF V600E is a determinant of sensitivity to proteasome inhibitors. PMID: 24107445 Ref: Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. PMID: 24114668 Ref: Increased TGF-alpha as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. PMID: 24122793 Ref: Use of molecular biomarkers to inform adjuvant therapy for colon cancer. PMID: 24133820 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. PMID: 24151533 Ref: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway. PMID: 24152305 Ref: [Clinical-pathological features and gene profile in colorectal cancer]. PMID: 24152396 Ref: PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. PMID: 24156022 Ref: A perspective on the current management of advanced colorectal cancer. PMID: 24156327 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. PMID: 24190114 Ref: Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. PMID: 24196786 Ref: Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. PMID: 24200637 Ref: Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PMID: 24205021 Ref: Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. PMID: 24210078 Ref: The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells. PMID: 24211581 Ref: Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. PMID: 24231454 Ref: Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PMID: 24244687 Ref: Evaluating many treatments and biomarkers in oncology: a new design. PMID: 24248692 Ref: Molecular diagnostics in colorectal carcinoma. PMID: 24267189 Ref: Personalized treatment for advanced colorectal cancer: KRAS and beyond. PMID: 24294007 Ref: Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report. PMID: 24304820 Ref: Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. PMID: 24307987 Ref: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. PMID: 24330663 Ref: Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PMID: 24339949 Ref: RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. PMID: 24356563 Ref: Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. PMID: 24379565 Ref: [Outcomes of patients with small bowel carcinoma treated with appropriate chemotherapy selected on the basis of genetic analysis findings]. PMID: 24393898 Ref: [A case of recurrent rectal cancer successfully treated for a long period with capecitabine plus oxaliplatin and bevacizumab therapy]. PMID: 24393995 Ref: Oncologists' attitudes toward KRAS testing: a multisite study. PMID: 24403261 Ref: KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature. PMID: 24422958 Ref: Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. PMID: 24440976 Ref: Rhabdoid carcinoma of the rectum. PMID: 24466541 Ref: [KRAS gene mutation in colorectal cancer]. PMID: 24522420 Ref: Inhibition of beta-catenin and KRAS expressions by Piper betle in azoxymethane-induced colon cancer of male Fischer 344 rats. PMID: 24617038 Ref: [The frequency and spectrum of KRAS mutations in metastatic colorectal cancer]. PMID: 24624786 Ref: Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. PMID: 24649163 Ref: Biomarkers in precision therapy in colorectal cancer. PMID: 24759962 Ref: Clinical implications of BRAF mutation test in colorectal cancer. PMID: 24834238 Ref: Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma. PMID: 29147353 |
Ref: Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India. PMID: 23168910 Ref: A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. PMID: 23211222 Ref: Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. PMID: 23299277 Ref: Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. PMID: 23493335 Ref: Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. PMID: 23542178 Ref: Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. PMID: 23568716 Ref: Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited? PMID: 23588415 Ref: MUTYH-associated colorectal cancer and adenomatous polyposis. PMID: 23605219 Ref: Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PMID: 23755178 Ref: Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. PMID: 23792451 Ref: VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. PMID: 23794399 Ref: Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. PMID: 23887306 Ref: Options for metastatic colorectal cancer beyond the second line of treatment. PMID: 23954144 Ref: Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. PMID: 23959273 Ref: A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. PMID: 23975373 Ref: Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. PMID: 24006244 Ref: KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. PMID: 24022727 Ref: Clinical relevance of KRAS mutations in codon 13: Where are we? PMID: 24051306 Ref: Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. PMID: 24061861 Ref: miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. PMID: 24098024 Ref: KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. PMID: 24136682 Ref: Brain metastases from colorectal cancer: main clinical factors conditioning outcome. PMID: 24158623 Ref: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. PMID: 24163374 Ref: Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. PMID: 24166180 Ref: Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. PMID: 24170544 Ref: FXR silencing in human colon cancer by DNA methylation and KRAS signaling. PMID: 24177031 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24195503 Ref: A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma. PMID: 24242294 Ref: Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. PMID: 24242331 Ref: Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience. PMID: 24246276 Ref: Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. PMID: 24258455 Ref: KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. PMID: 24259266 Ref: Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. PMID: 24262587 Ref: EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. PMID: 24281417 Ref: Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. PMID: 24282149 Ref: MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. PMID: 24293274 Ref: PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine. PMID: 24293351 Ref: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. PMID: 24296758 Ref: KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. PMID: 24331409 Ref: Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. PMID: 24351336 Ref: Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. PMID: 24352906 Ref: DNA testing and molecular screening for colon cancer. PMID: 24355100 Ref: The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients. PMID: 24378613 Ref: Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. PMID: 24379162 Ref: Fusobacterium in colonic flora and molecular features of colorectal carcinoma. PMID: 24385213 Ref: Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. PMID: 24390240 Ref: Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC. PMID: 24398672 Ref: Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. PMID: 24403498 Ref: [Clinical application of next-generation sequencing technologies to achieve cancer precision medicine]. PMID: 24423944 Ref: Is biomarker research advancing in the era of personalized medicine for head and neck cancer? PMID: 24442754 Ref: TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations. PMID: 24443225 Ref: DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy. PMID: 24456329 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). PMID: 24465639 Ref: p120RasGAP is a mediator of rho pathway activation and tumorigenicity in the DLD1 colorectal cancer cell line. PMID: 24465899 Ref: Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status. PMID: 24467518 Ref: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. PMID: 24468885 Ref: KRAS and cancer stem cells in APC-mutant colorectal cancer. PMID: 24491303 Ref: The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. PMID: 24495042 Ref: GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PMID: 24498230 Ref: Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 24500024 Ref: SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. PMID: 24503755 Ref: Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. PMID: 24505265 Ref: Melting curve analysis for mutations of EGFR and KRAS. PMID: 24510990 Ref: Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. PMID: 24516257 Ref: CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. PMID: 24518818 Ref: Biallelic MUTYH mutations can mimic Lynch syndrome. PMID: 24518836 Ref: Spectrum of K ras mutations in Pakistani colorectal cancer patients. PMID: 24519090 Ref: Adrenomedullin is a therapeutic target in colorectal cancer. PMID: 24519534 Ref: Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? PMID: 24520223 Ref: Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. PMID: 24521660 Ref: Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. PMID: 24523613 Ref: PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. PMID: 24530606 Ref: KRAS mutations: analytical considerations. PMID: 24534449 Ref: RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. PMID: 24548858 Ref: Detection of circulating tumor DNA in early- and late-stage human malignancies. PMID: 24553385 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. PMID: 24558128 Ref: KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. PMID: 24558511 Ref: EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. PMID: 24560515 Ref: Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population. PMID: 24570042 Ref: Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. PMID: 24576621 Ref: RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. PMID: 24582914 Ref: FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PMID: 24586741 Ref: Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. PMID: 24590867 Ref: KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? PMID: 24594115 Ref: Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). PMID: 24595526 Ref: EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. PMID: 24595598 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. PMID: 24599131 Ref: Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PMID: 24599305 Ref: Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. PMID: 24603588 Ref: Distinct profile of HIF1alpha, PTCH, EphB2, or DNA repair protein expression and BRAF mutation in colorectal serrated adenoma. PMID: 24612059 Ref: Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. PMID: 24621249 Ref: A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. PMID: 24623306 Ref: Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. PMID: 24626880 Ref: Masking epistasis between MYC and TGF-beta pathways in antiangiogenesis-mediated colon cancer suppression. PMID: 24627270 Ref: Serrated pathway in colorectal carcinogenesis. PMID: 24627599 Ref: Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. PMID: 24631467 Ref: Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras. PMID: 24632531 Ref: [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma]. PMID: 24635436 Ref: Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan. PMID: 24642668 Ref: Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. PMID: 24642870 Ref: Multiple sporadic colorectal cancers display a unique methylation phenotype. PMID: 24643221 Ref: Multitarget stool DNA testing for colorectal-cancer screening. PMID: 24645800 Ref: The Presence of Mutations in the K-RAS Gene Does Not Affect Survival after Resection of Pulmonary Metastases from Colorectal Cancer. PMID: 24649376 Ref: Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients. PMID: 24653752 Ref: Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. PMID: 24659028 Ref: Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis. PMID: 24659647 Ref: Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines. PMID: 24659889 Ref: RNA editing in RHOQ promotes invasion potential in colorectal cancer. PMID: 24663214 Ref: Highly sensitive KRAS mutation detection from formalin-fixed paraffin-embedded biopsies and circulating tumour cells using wild-type blocking polymerase chain reaction and Sanger sequencing. PMID: 24664550 Ref: Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. PMID: 24668895 Ref: DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. PMID: 24674026 Ref: Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. PMID: 24675495 Ref: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PMID: 24676216 Ref: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. PMID: 24685132 Ref: Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. PMID: 24685572 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. PMID: 24695225 Ref: Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases. PMID: 24696747 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. PMID: 24703531 Ref: Genetic mechanisms in interval colon cancers. PMID: 24705641 Ref: Colorectal cancer risk and patients' survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. PMID: 24706189 Ref: Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. PMID: 24718513 Ref: KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. PMID: 24720724 Ref: Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). PMID: 24727325 Ref: Successes and limitations of targeted cancer therapy in colon cancer. PMID: 24727985 Ref: Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. PMID: 24733427 Ref: Targeting EGFR in colorectal cancer: beyond KRAS exon 2. PMID: 24739895 Ref: [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. PMID: 24742565 Ref: Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease. PMID: 24742783 Ref: [A case of curatively resected sigmoid colon cancer after mFOLFOX6 plus panitumumab neoadjuvant chemotherapy]. PMID: 24743293 Ref: Moguntinones--new selective inhibitors for the treatment of human colorectal cancer. PMID: 24743703 Ref: A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? PMID: 24743706 Ref: Molecular analysis of liquid cytological samples collected by bronchoscopy with radial endobronchial ultrasonography and guide sheath. PMID: 24747549 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort. PMID: 24763823 Ref: Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. PMID: 24764675 Ref: KRAS and BRAF genotyping of synchronous colorectal carcinomas. PMID: 24765171 Ref: Real-time bidirectional pyrophosphorolysis-activated polymerization for quantitative detection of somatic mutations. PMID: 24769870 Ref: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. PMID: 24778007 Ref: Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. PMID: 24778079 Ref: Intestinal type of lung adenocarcinoma in younger adults. PMID: 24782938 Ref: Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PMID: 24788807 Ref: Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. PMID: 24793120 Ref: The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. PMID: 24793846 Ref: BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. PMID: 24798160 Ref: Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. PMID: 24798213 Ref: Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. PMID: 24798549 Ref: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. PMID: 24799053 Ref: Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. PMID: 24800948 Ref: Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. PMID: 24806883 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Rectal site and suboptimal nodal yield predict systemic recurrence in resected colorectal carcinoma: a case-control study. PMID: 24813440 Ref: Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. PMID: 24816724 Ref: Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-beta. PMID: 24825889 Ref: Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. PMID: 24832158 Ref: RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. PMID: 24833563 Ref: Targeting CD137 enhances the efficacy of cetuximab. PMID: 24837434 Ref: Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. PMID: 24839940 Ref: Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. PMID: 24841217 Ref: Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. PMID: 24841357 Ref: A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. PMID: 24844134 Ref: Colorectal advanced neoplasms occur through dual carcinogenesis pathways in individuals with coexisting serrated polyps. PMID: 24849572 Ref: Circulating free DNA in a screening program for early colorectal cancer detection. PMID: 24852853 Ref: KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer. PMID: 24852854 Ref: The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. PMID: 24857065 Ref: CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. PMID: 24859205 Ref: Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients. PMID: 24859378 Ref: Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. PMID: 24859528 Ref: KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. PMID: 24859998 Ref: [BRAF gene mutation in wild-type KRAS patients with colorectal cancers]. PMID: 24861115 Ref: Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer. PMID: 24861525 Ref: Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. PMID: 24861917 Ref: Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. PMID: 24863535 Ref: Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. PMID: 24863805 Ref: Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. PMID: 24880666 Ref: Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. PMID: 24884535 Ref: Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. PMID: 24885062 Ref: Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer. PMID: 24887488 Ref: Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. PMID: 24890702 Ref: Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. PMID: 24894453 Ref: Nuclear adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice. PMID: 24894865 Ref: Correlation between the presence of KRAS mutation and the morphometric characteristics of colorectal carcinoma cell nuclei. PMID: 24902368 Ref: Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer. PMID: 24906690 Ref: Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability. PMID: 24909058 Ref: Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. PMID: 24913355 Ref: Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. PMID: 24915895 Ref: Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. PMID: 24916545 Ref: TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. PMID: 24916700 Ref: Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PMID: 24918610 Ref: Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. PMID: 24920642 Ref: Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. PMID: 24925349 Ref: CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. PMID: 24928946 Ref: ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. PMID: 24931611 Ref: Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer. PMID: 24932174 Ref: 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. PMID: 24932229 Ref: Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. PMID: 24935274 Ref: Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PMID: 24940619 Ref: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. PMID: 24942275 Ref: The BRAF mutation is associated with the prognosis in colorectal cancer. PMID: 24942334 Ref: Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. PMID: 24943349 Ref: Colorectal cancer: from prevention to personalized medicine. PMID: 24944469 Ref: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin. PMID: 24944587 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. PMID: 24953332 Ref: KRAS and YAP1 converge to regulate EMT and tumor survival. PMID: 24954536 Ref: Efficacy of cetuximab in metastatic colon cancer - case report. PMID: 24956345 Ref: TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. PMID: 24957073 Ref: Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. PMID: 24960403 Ref: Hyperplastic polyps identified during screening endoscopy: reevaluated by histological examinations and genetic alterations. PMID: 24961182 Ref: Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. PMID: 24962990 Ref: The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. PMID: 24964758 Ref: DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. PMID: 24964857 Ref: Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip. PMID: 24964961 Ref: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. PMID: 24970817 Ref: Correlation between PET/CT parameters and KRAS expression in colorectal cancer. PMID: 24978328 Ref: Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. PMID: 24990411 Ref: RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. PMID: 24996433 Ref: Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation. PMID: 24998492 Ref: Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. PMID: 25004944 Ref: A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. PMID: 25005754 Ref: Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. PMID: 25009008 Ref: SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer. PMID: 25010701 Ref: Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. PMID: 25013126 Ref: An oligonucleotide-tagged microarray for routine diagnostics of colon cancer by genotyping KRAS mutations. PMID: 25018048 Ref: SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. PMID: 25023548 Ref: The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening. PMID: 25025467 Ref: Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study. PMID: 25029614 Ref: Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. PMID: 25032217 Ref: KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. PMID: 25050586 Ref: Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. PMID: 25051912 Ref: Biomarker-based treatment selection in early-stage rectal cancer to promote organ preservation. PMID: 25052224 Ref: Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer. PMID: 25052499 Ref: Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices. PMID: 25065655 Ref: Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population. PMID: 25069446 Ref: Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. PMID: 25073438 Ref: Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. PMID: 25074246 Ref: Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. PMID: 25075098 Ref: Quantitative proteomics reveals differentially expressed proteins in murine preneoplastic intestine in a model of intestinal tumorigenesis induced by low dietary folate and MTHFR deficiency. PMID: 25081070 Ref: KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. PMID: 25083299 Ref: Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PMID: 25083765 Ref: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. PMID: 25088940 Ref: Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PMID: 25090459 Ref: Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PMID: 25093594 Ref: Development of siRNA payloads to target KRAS-mutant cancer. PMID: 25100204 Ref: Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. PMID: 25110411 Ref: IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. PMID: 25110432 Ref: Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment. PMID: 25124163 Ref: [Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment-a case report]. PMID: 25131880 Ref: Personalizing medicine for metastatic colorectal cancer: current developments. PMID: 25132758 Ref: Paracrine network: another step in the complexity of resistance to EGFR blockade? PMID: 25139340 Ref: KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. PMID: 25155157 Ref: Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis. PMID: 25157365 Ref: Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. PMID: 25158139 Ref: Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy. PMID: 25162504 Ref: Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. PMID: 25164765 Ref: Electrochemical biosensor based on functional composite nanofibers for detection of K-ras gene via multiple signal amplification strategy. PMID: 25173509 Ref: A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. PMID: 25183481 Ref: Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. PMID: 25190725 Ref: Phospholipase Cdelta1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells. PMID: 25197077 Ref: KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. PMID: 25197873 Ref: EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells. PMID: 25198428 Ref: KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. PMID: 25202344 Ref: Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. PMID: 25209093 Ref: The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. PMID: 25210463 Ref: [Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population]. PMID: 25216999 Ref: Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells. PMID: 25245095 Ref: Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. PMID: 25246275 Ref: 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PMID: 25247710 Ref: PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis. PMID: 25260023 Ref: High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. PMID: 25262986 Ref: KRAS and BRAF mutational status in colon cancer from Albanian patients. PMID: 25267307 Ref: Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment. PMID: 25275049 Ref: Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. PMID: 25280562 Ref: Therapeutic silencing of KRAS using systemically delivered siRNAs. PMID: 25281617 Ref: MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. PMID: 25287248 Ref: Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. PMID: 25293556 Ref: Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. PMID: 25309914 Ref: Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. PMID: 25313182 Ref: Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. PMID: 25324142 Ref: Somatic mutations of the HER2 in metastatic breast cancer. PMID: 25326805 Ref: Colorectal cancer in Chinese patients: current and emerging treatment options. PMID: 25336973 Ref: Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. PMID: 25337237 Ref: MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. PMID: 25342918 Ref: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. PMID: 25367198 Ref: Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. PMID: 25368289 Ref: Panitumumab in the treatment of colon cancer: A biomarker dilemma. PMID: 25374966 Ref: The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity. PMID: 25379018 Ref: Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. PMID: 25379021 Ref: The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer. PMID: 25383169 Ref: Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer. PMID: 25386108 Ref: Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. PMID: 25389372 Ref: LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms. PMID: 25394300 Ref: Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PMID: 25401499 Ref: Novel KRAS gene mutations in sporadic colorectal cancer. PMID: 25412182 Ref: Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). PMID: 25417182 Ref: [Application of molecular targeted agents in comprehensive treatment of gastrointestinal cancer]. PMID: 25421761 Ref: [Safety and efficacy analysis on modified FOLFOXIRI as first-line treatment for advanced colorectal cancer in China-single center experience]. PMID: 25421765 Ref: E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. PMID: 25425971 Ref: c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation. PMID: 25427200 Ref: Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. PMID: 25427581 Ref: Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. PMID: 25432628 Ref: Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis. PMID: 25437589 Ref: Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. PMID: 25444464 Ref: Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. PMID: 25453050 Ref: Recent applications of chemosensitivity tests for colorectal cancer treatment. PMID: 25469008 Ref: [Detection of KRAS gene mutations in colorectal carcinoma: a study of 6 364 patients]. PMID: 25471497 Ref: TroVax in colorectal cancer. PMID: 25483641 Ref: CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. PMID: 25484061 Ref: Mini profile of potential anticancer properties of propofol. PMID: 25502773 Ref: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. PMID: 25515240 Ref: Establishment of genetically diverse patient-derived xenografts of colorectal cancer. PMID: 25520871 Ref: Management of colorectal cancer. PMID: 25580262 Ref: Immunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin. PMID: 25593974 Ref: Molecular pathology of colorectal cancer. PMID: 25693079 Ref: [KRAS gene somatic mutations in Chilean patients with colorectal cancer]. PMID: 25694286 Ref: Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. PMID: 25713627 Ref: Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer. PMID: 25713893 Ref: [Surgical resection after chemotherapy for advanced rectal cancer - report of a case]. PMID: 25731256 Ref: [A case of postoperative colon cancer with peritoneal dissemination in which a long-term response was achieved using panitumumab maintenance therapy]. PMID: 25731301 Ref: [A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)]. PMID: 25731316 Ref: [Mixed adenoneuroendocrine carcinoma with multiple liver metastases successfully treated by cetuximab/CPT-11 chemotherapy followed by curative resection - a case report]. PMID: 25731451 Ref: [The alternative way of colorectal cancer developing. The histogenetic and molecular features of serrated lesions (review, continued)]. PMID: 25842399 Ref: PMID: 25905152 Ref: Akt mediated ROS-dependent selective targeting of mutant KRAS tumors. PMID: 26461287 Ref: Colorectal Cancer: Personalized Therapy. PMID: 26676107 Ref: Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. PMID: 26763794 Ref: Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. PMID: 26842186 Ref: Molecular Diagnostic Applications in Colorectal Cancer. PMID: 27600342 |
Ref: K-Ras, intestinal homeostasis and colon cancer. PMID: 24219000 Ref: Correlation of dynamic contrast-enhanced MRI perfusion parameters with angiogenesis and biologic aggressiveness of rectal cancer: Preliminary results. PMID: 24375840 Ref: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. PMID: 24469059 Ref: Personalised cancer medicine. PMID: 24789362 Ref: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. PMID: 24791855 Ref: Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. PMID: 24806288 Ref: Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. PMID: 24870621 Ref: KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. PMID: 24889488 Ref: Distinct WNT/beta-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. PMID: 24925057 Ref: Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. PMID: 24951259 Ref: Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. PMID: 25081749 Ref: Engineering plasmonic nanorod arrays for colon cancer marker detection. PMID: 25129509 Ref: Genetic analysis of colon tumors induced by a dietary carcinogen PhIP in CYP1A humanized mice: Identification of mutation of beta-catenin/Ctnnb1 as the driver gene for the carcinogenesis. PMID: 25131582 Ref: A clinicopathological and molecular analysis of 200 traditional serrated adenomas. PMID: 25216220 Ref: Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. PMID: 25236593 Ref: Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. PMID: 25248381 Ref: Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. PMID: 25248721 Ref: Identification of novel mutations by exome sequencing in African American colorectal cancer patients. PMID: 25250560 Ref: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. PMID: 25256312 Ref: Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy. PMID: 25269837 Ref: Association between molecular subtypes of colorectal cancer and patient survival. PMID: 25280443 Ref: Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. PMID: 25305448 Ref: Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. PMID: 25305506 Ref: Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. PMID: 25311193 Ref: KRAS mutation status impacts diagnosis and treatment decision in a patient with two colon tumours: a case report. PMID: 25313410 Ref: Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. PMID: 25319061 Ref: Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. PMID: 25326395 Ref: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. PMID: 25326806 Ref: Medullary carcinoma of the colon: can the undifferentiated be differentiated? PMID: 25339302 Ref: Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. PMID: 25359494 Ref: Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. PMID: 25361982 Ref: Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. PMID: 25366420 Ref: Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. PMID: 25373533 Ref: Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. PMID: 25378536 Ref: Some economics on personalized and predictive medicine. PMID: 25381039 Ref: Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. PMID: 25381643 Ref: Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. PMID: 25382057 Ref: Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. PMID: 25388162 Ref: Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. PMID: 25388166 Ref: Serial in vivo imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy. PMID: 25397907 Ref: MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. PMID: 25403854 Ref: Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. PMID: 25410095 Ref: Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. PMID: 25412235 Ref: Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics. PMID: 25418895 Ref: Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? PMID: 25420993 Ref: Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer. PMID: 25436008 Ref: Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. PMID: 25446878 Ref: Portrait of the PI3K/AKT pathway in colorectal cancer. PMID: 25450577 Ref: Genome-wide analysis of long noncoding RNA signature in human colorectal cancer. PMID: 25456707 Ref: Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. PMID: 25469291 Ref: Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PMID: 25472647 Ref: KRAS mutation testing in clinical practice. PMID: 25487540 Ref: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. PMID: 25491172 Ref: MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study. PMID: 25496852 Ref: Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. PMID: 25500543 Ref: Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. PMID: 25514114 Ref: LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo. PMID: 25524577 Ref: IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. PMID: 25527633 Ref: Serrated and non-serrated precursor lesions of colorectal cancer. PMID: 25531494 Ref: Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. PMID: 25532759 Ref: Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue. PMID: 25545608 Ref: Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. PMID: 25548100 Ref: ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. PMID: 25553091 Ref: K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. PMID: 25561545 Ref: KRAS mutation analysis by PCR: a comparison of two methods. PMID: 25568935 Ref: Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. PMID: 25572811 Ref: CD44-SLC1A2 fusion transcripts in primary colorectal cancer. PMID: 25576211 Ref: Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. PMID: 25589625 Ref: Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases. PMID: 25589885 Ref: Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. PMID: 25593032 Ref: Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations. PMID: 25599653 Ref: Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. PMID: 25605225 Ref: Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. PMID: 25605843 Ref: TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. PMID: 25608838 Ref: KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. PMID: 25609577 Ref: Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers. PMID: 25611103 Ref: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. PMID: 25623215 Ref: Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. PMID: 25623536 Ref: Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. PMID: 25628445 Ref: Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. PMID: 25628921 Ref: Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. PMID: 25632202 Ref: Clinicopathological and molecular characteristics of serrated lesions in Japanese elderly patients. PMID: 25632919 Ref: Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. PMID: 25637035 Ref: Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. PMID: 25637165 Ref: Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. PMID: 25638164 Ref: Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. PMID: 25639985 Ref: Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population. PMID: 25647260 Ref: Whole genome amplification induced bias in the detection of KRAS-mutated cell populations during colorectal carcinoma tissue testing. PMID: 25655305 Ref: External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. PMID: 25657200 Ref: Molecular markers predictive of chemotherapy response in colorectal cancer. PMID: 25663616 Ref: Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. PMID: 25663765 Ref: MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways. PMID: 25663768 Ref: KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. PMID: 25663779 Ref: EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. PMID: 25663927 Ref: Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. PMID: 25664394 Ref: FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. PMID: 25666295 Ref: Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. PMID: 25666296 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. PMID: 25674493 Ref: Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. PMID: 25680623 Ref: Novel molecular insights from routine genotyping of colorectal carcinomas. PMID: 25683705 Ref: Colorectal cancer in iran: molecular epidemiology and screening strategies. PMID: 25685149 Ref: Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer? PMID: 25687873 Ref: Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. PMID: 25688736 Ref: KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. PMID: 25688918 Ref: Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences. PMID: 25696795 Ref: Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. PMID: 25699236 Ref: Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. PMID: 25702261 Ref: Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study. PMID: 25703078 Ref: KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology. PMID: 25706807 Ref: Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. PMID: 25706875 Ref: Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma. PMID: 25708741 Ref: Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. PMID: 25712343 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. PMID: 25734426 Ref: Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. PMID: 25742472 Ref: High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. PMID: 25742883 Ref: [A successful multimodality therapy for a case of recurrent rectal cancer with KRAS mutation]. PMID: 25743147 Ref: Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer. PMID: 25750328 Ref: Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. PMID: 25756961 Ref: [Implementation of standard operation procedures for KRAS andBRAF gene mutation detection in colorectal cancer]. PMID: 25765033 Ref: KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. PMID: 25778307 Ref: Costs and effectiveness of genomic testing in the management of colorectal cancer. PMID: 25783977 Ref: P53 mutations occur more commonly than KRAS mutations in colorectal adenoma. PMID: 25785139 Ref: Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. PMID: 25786087 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. PMID: 25797890 Ref: Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. PMID: 25799948 Ref: Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. PMID: 25800101 Ref: Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. PMID: 25805818 Ref: Personalized treatment for patients with colorectal cancer: role of biomarkers. PMID: 25808438 Ref: Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. PMID: 25809746 Ref: Development of a gLCR-based KRAS mutation detection approach and its comparison with other screening methods. PMID: 25813150 Ref: Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. PMID: 25815366 Ref: Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. PMID: 25815786 Ref: Eprobe-mediated screening system for somatic mutations in the KRAS locus. PMID: 25823645 Ref: Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. PMID: 25826503 Ref: KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR. PMID: 25835782 Ref: Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. PMID: 25838391 Ref: Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery. PMID: 25840921 Ref: Selected case from the Arkadi M. Rywlin International Pathology Slide Club: carcinoma of the transverse colon in a young girl. PMID: 25844680 Ref: Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. PMID: 25851630 Ref: KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. PMID: 25853628 Ref: Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Delta716) mice involves stromal COX-2. PMID: 25855137 Ref: RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. PMID: 25859555 Ref: Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. PMID: 25861256 Ref: A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. PMID: 25861837 Ref: BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. PMID: 25862899 Ref: KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. PMID: 25864038 Ref: Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. PMID: 25870609 Ref: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin PMID: 25877855 Ref: Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. PMID: 25884297 Ref: Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. PMID: 25884643 Ref: HGUE-C-1 is an atypical and novel colon carcinoma cell line. PMID: 25885658 Ref: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. PMID: 25889309 Ref: Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells. PMID: 25889965 Ref: Improved survival among colon cancer patients with increased differentially expressed pathways. PMID: 25890236 Ref: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. PMID: 25896895 Ref: Longitudinal Tracing of Spontaneous Regression and Anti-angiogenic Response of Individual Microadenomas during Colon Tumorigenesis. PMID: 25897337 Ref: [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. PMID: 25899481 Ref: Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PMID: 25902072 Ref: Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. PMID: 25913614 Ref: Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. PMID: 25918287 Ref: MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. PMID: 25919696 Ref: Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. PMID: 25920359 Ref: Sequential cancer mutations in cultured human intestinal stem cells. PMID: 25924068 Ref: Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma. PMID: 25926041 Ref: The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. PMID: 25926745 Ref: Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. PMID: 25929517 Ref: (P050) Yttrium-90 Radioembolization for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases in KRAS Wild-type and Mutant Patients. PMID: 25930808 Ref: Biology of colorectal cancer. PMID: 25932044 Ref: Cancer mutation screening: Comparison of high-resolution melt analysis between two platforms. PMID: 25932046 Ref: KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. PMID: 25933688 Ref: Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo. PMID: 25934695 Ref: A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. PMID: 25936694 Ref: FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. PMID: 25937522 Ref: RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. PMID: 25944693 Ref: Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. PMID: 25946211 Ref: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PMID: 25954997 Ref: Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or PMID: 25956750 Ref: Familial breast cancer - targeted therapy in secondary and tertiary prevention. PMID: 25960722 Ref: Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. PMID: 25965827 Ref: CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. PMID: 25968046 Ref: Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PMID: 25970543 Ref: Endoscopic ultrasound fine-needle aspiration cytology mutation profiling using targeted next-generation sequencing: personalized care for rectal cancer. PMID: 25972331 Ref: Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. PMID: 25973297 Ref: A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. PMID: 25973306 Ref: Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PMID: 25974029 Ref: Comparison of high-resolution melting analysis, Sanger sequencing and ARMS for KRAS mutation detection in metastatic colorectal cancer. PMID: 25975014 Ref: [Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma]. PMID: 25975908 Ref: Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics. PMID: 25976417 Ref: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. PMID: 25979833 Ref: KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer? PMID: 25983749 Ref: Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. PMID: 25990448 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: RAS status in Korean patients with stage III and IV colorectal cancer. PMID: 25997687 Ref: Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. PMID: 25998052 Ref: Traditional serrated adenoma: an update. PMID: 26001333 Ref: Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. PMID: 26003673 Ref: [Molecular analysis of sporadic colon cancer]. PMID: 26005817 Ref: RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. PMID: 26005835 Ref: Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples. PMID: 26010451 Ref: Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT. PMID: 26018692 Ref: Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. PMID: 26019172 Ref: PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation. PMID: 26019684 Ref: Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PMID: 26024321 Ref: Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. PMID: 26026309 Ref: Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. PMID: 26027741 Ref: Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. PMID: 26028667 Ref: The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement. PMID: 26029033 Ref: Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. PMID: 26029459 Ref: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. PMID: 26030179 Ref: Molecular and histologic considerations in the assessment of serrated polyps. PMID: 26030242 Ref: KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers. PMID: 26031776 Ref: Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. PMID: 26033452 Ref: Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. PMID: 26042813 Ref: Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. PMID: 26053280 Ref: Somatic c.34G>T KRAS mutation: a new prescreening test for MUTYH-associated polyposis? PMID: 26056087 Ref: Positive feedback between oncogenic KRAS and HIF-1alpha confers drug resistance in colorectal cancer. PMID: 26060408 Ref: Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. PMID: 26064214 Ref: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. PMID: 26074686 Ref: Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. PMID: 26077004 Ref: Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. PMID: 26077270 Ref: Identification and characterization of RET fusions in advanced colorectal cancer. PMID: 26078337 Ref: Standard chemotherapy with cetuximab for treatment of colorectal cancer. PMID: 26078581 Ref: The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order. PMID: 26081767 Ref: The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. PMID: 26086204 Ref: Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. PMID: 26090075 Ref: Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. PMID: 26091037 Ref: Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. PMID: 26092596 Ref: EGFR and beta1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. PMID: 26096850 Ref: A Transition Zone Showing Highly Discontinuous or Alternating Levels of Stem Cell and Proliferation Markers Characterizes the Development of PTEN-Haploinsufficient Colorectal Cancer. PMID: 26098881 Ref: The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. PMID: 26104296 Ref: Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma. PMID: 26106602 Ref: Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis. PMID: 26107680 Ref: Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. PMID: 26109816 Ref: EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. PMID: 26110767 Ref: Stem vs non-stem cell origin of colorectal cancer. PMID: 26110974 Ref: Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor beta-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells. PMID: 26114584 Ref: KRAS and aneusomy of chromosomes 4, 10 and 12 in colorectal carcinomas. PMID: 26122820 Ref: KRAS-dependent sorting of miRNA to exosomes. PMID: 26132860 Ref: Genetic mutations in human rectal cancers detected by targeted sequencing. PMID: 26134512 Ref: Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. PMID: 26135109 Ref: Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. PMID: 26136684 Ref: Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. PMID: 26137573 Ref: Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. PMID: 26160607 Ref: The Hippo pathway in colorectal cancer. PMID: 26160682 Ref: Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. PMID: 26160882 Ref: KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. PMID: 26161928 Ref: Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. PMID: 26162609 Ref: Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples. PMID: 26163758 Ref: Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules. PMID: 26168486 Ref: In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. PMID: 26168967 Ref: Gene expression in colon cancer: A focus on tumor site and molecular phenotype. PMID: 26171582 Ref: LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. PMID: 26172297 Ref: Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. PMID: 26181352 Ref: Computed tomography assessment of early response to neoadjuvant therapy in colon cancer. PMID: 26183044 Ref: Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors. PMID: 26185002 Ref: Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). PMID: 26187617 Ref: MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer. PMID: 26189482 Ref: Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping. PMID: 26189770 Ref: Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer. PMID: 26196590 Ref: [A Case of Rectal Cancer with Portal Vein Tumor Thrombosis Successfully Treated with First-Line Panitumumab Monotherapy]. PMID: 26197754 Ref: Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. PMID: 26200097 Ref: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. PMID: 26206254 Ref: Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer. PMID: 26206338 Ref: KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. PMID: 26210240 Ref: Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. PMID: 26216840 Ref: Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. PMID: 26218848 Ref: Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. PMID: 26220423 Ref: Focus on 16p13.3 Locus in Colon Cancer. PMID: 26222184 Ref: An Integrative Approach for Mapping Differentially Expressed Genes and Network Components Using Novel Parameters to Elucidate Key Regulatory Genes in Colorectal Cancer. PMID: 26222778 Ref: Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. PMID: 26226847 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. PMID: 26231173 Ref: Coexisting KRAS and NRAS mutations in colon cancer. PMID: 26243064 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. PMID: 26245900 Ref: Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. PMID: 26252055 Ref: KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. PMID: 26252300 Ref: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. PMID: 26258891 Ref: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. PMID: 26272063 Ref: Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence. PMID: 26276752 Ref: Hypothesis: Obesity Is Associated with a Lower Mutation Threshold in Colon Cancer. PMID: 26284133 Ref: Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. PMID: 26291085 Ref: Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. PMID: 26299805 Ref: [Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients]. PMID: 26299862 Ref: Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. PMID: 26305864 Ref: K-ras genetic mutation and influencing factor analysis for Han and Uygur nationality colorectal cancer patients. PMID: 26309716 Ref: KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. PMID: 26318594 Ref: MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. PMID: 26322950 Ref: KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? PMID: 26325103 Ref: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. PMID: 26327923 Ref: ITF-2B protein levels are correlated with favorable prognosis in patients with colorectal carcinomas. PMID: 26328254 Ref: Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002). PMID: 26334293 Ref: The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. PMID: 26335936 Ref: Clonal origins and parallel evolution of regionally synchronous colorectal adenoma and carcinoma. PMID: 26336987 Ref: Molecular phenotypes of colorectal cancer and potential clinical applications. PMID: 26337942 Ref: Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. PMID: 26347132 Ref: Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. PMID: 26351067 Ref: Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. PMID: 26351322 Ref: KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. PMID: 26352110 Ref: Young age of onset colorectal cancers. PMID: 26358068 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. PMID: 26361422 Ref: Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PMID: 26366557 Ref: High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PMID: 26375816 Ref: K-ras Mutation in Colorectal Cancer, A Report from Southern Iran. PMID: 26379353 Ref: Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients. PMID: 26386973 Ref: Stool DNA methylation assays in colorectal cancer screening. PMID: 26401070 Ref: Serrated colorectal polyps in inflammatory bowel disease. PMID: 26403785 Ref: Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. PMID: 26404261 Ref: Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. PMID: 26406410 Ref: The genomic landscape of response to EGFR blockade in colorectal cancer. PMID: 26416732 Ref: Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. PMID: 26418750 Ref: Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. PMID: 26423386 Ref: DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. PMID: 26426205 Ref: c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer. PMID: 26426996 Ref: KRAS gene mutations - prognostic factor in colorectal cancer? PMID: 26429158 Ref: Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. PMID: 26435479 Ref: Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer. PMID: 26439033 Ref: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. PMID: 26439693 Ref: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. PMID: 26449765 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. PMID: 26460303 Ref: Optimizing Anti-EGFR Therapy in Colorectal Cancer. PMID: 26463710 Ref: Large Bowel Genetic Background and Inflammatory Processes in Carcinogenesis--Systematic Review. PMID: 26469098 Ref: Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. PMID: 26476438 Ref: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. PMID: 26486455 Ref: Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas. PMID: 26488212 Ref: [Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib]. PMID: 26489551 Ref: Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. PMID: 26491871 Ref: Identification of O-Linked Glycoproteins Binding to the Lectin Helix pomatia Agglutinin as Markers of Metastatic Colorectal Cancer. PMID: 26495974 Ref: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. PMID: 26498038 Ref: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. PMID: 26508446 Ref: A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. PMID: 26512781 Ref: Mutational profiling of colorectal cancers with microsatellite instability. PMID: 26517354 Ref: Colorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability. PMID: 26523369 Ref: [Fecal Biomarker for Colorectal Cancer Diagnosis]. PMID: 26524859 Ref: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. PMID: 26525741 Ref: Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. PMID: 26530529 Ref: Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. PMID: 26541605 Ref: rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population. PMID: 26543374 Ref: Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. PMID: 26553291 Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. PMID: 26553611 Ref: Molecular Features and Methylation Status in Early Onset ( PMID: 26557847 Ref: Absolute Quantification of Endogenous Ras Isoform Abundance. PMID: 26560143 Ref: Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. PMID: 26561209 Ref: Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study. PMID: 26566372 Ref: Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines. PMID: 26581653 Ref: Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. PMID: 26586952 Ref: [Companion Diagnostics Sub-Section of Anatomic Pathology Department in a Mid-Sized General Hospital: Start Up and Maintenance]. PMID: 26591440 Ref: [A Case of Complete Pathological Response in a Patient with Locally Advanced Sigmoid Colon Cancer after FOLFOX IRI Chemotherapy]. PMID: 26602406 Ref: Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. PMID: 26604793 Ref: Biomarker-directed Targeted Therapy in Colorectal Cancer. PMID: 26609516 Ref: Treatment Individualization in Colorectal Cancer. PMID: 26617477 Ref: Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype. PMID: 26618628 Ref: Microsatellite instability in colorectal cancer: clinicopathological significance. PMID: 26619098 Ref: Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. PMID: 26622684 Ref: Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. PMID: 26623049 Ref: Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. PMID: 26640390 Ref: Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. PMID: 26673925 Ref: MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. PMID: 26677401 Ref: Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PMID: 26678268 Ref: Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria. PMID: 26681025 Ref: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. PMID: 26691448 Ref: Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. PMID: 26697123 Ref: Impact of somatic mutations on patterns of metastasis in colorectal cancer. PMID: 26697197 Ref: Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. PMID: 26697204 Ref: Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations. PMID: 26701781 Ref: [Evaluation and application of methods for KRAS gene mutation detection in colorectal cancer]. PMID: 26704847 Ref: KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism. PMID: 26709701 Ref: Multiple pathways regulate Cten in colorectal cancer without a Tensin switch. PMID: 26852686 Ref: The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection. PMID: 26897942 Ref: Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. PMID: 26902020 Ref: [Companion Diagnostics for Solid Tumors]. PMID: 26995877 Ref: Modulation of tumorigenesis by the pro-inflammatory microRNA miR-301a in mouse models of lung cancer and colorectal cancer. PMID: 27462406 Ref: Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device. PMID: 27600219 Ref: The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. PMID: 28162292 Ref: KRAS Cold Turkey: Using microRNAs to target KRAS-addicted cancer. PMID: 29367950 |
Ref: Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. PMID: 24517959 Ref: Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. PMID: 25913616 Ref: UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. PMID: 25917796 Ref: p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 25943321 Ref: Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. PMID: 26001389 Ref: Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. PMID: 26122021 Ref: Selective beta2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis. PMID: 26189563 Ref: Serrated tubulovillous adenoma of the large intestine. PMID: 26212352 Ref: Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. PMID: 26224873 Ref: Colorectal cancer metastatic to the brain: analysis of prognostic factors and impact of KRAS mutations on presentation and outcome. PMID: 26260912 Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. PMID: 26283684 Ref: Modal variety of microsatellite instability in human endometrial carcinomas. PMID: 26298837 Ref: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. PMID: 26311717 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. PMID: 26350752 Ref: Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. PMID: 26361962 Ref: Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. PMID: 26369631 Ref: Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. PMID: 26376292 Ref: MicroRNA MIR21 and T Cells in Colorectal Cancer. PMID: 26419959 Ref: Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. PMID: 26437179 Ref: Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. PMID: 26438111 Ref: Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer. PMID: 26456957 Ref: Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis. PMID: 26471487 Ref: The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential. PMID: 26476272 Ref: Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. PMID: 26490308 Ref: Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions. PMID: 26496853 Ref: Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. PMID: 26496897 Ref: Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome. PMID: 26500331 Ref: Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. PMID: 26512054 Ref: KRAS polymorphisms are associated with survival of CRC in Chinese population. PMID: 26515332 Ref: NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. PMID: 26515606 Ref: Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. PMID: 26536055 Ref: Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. PMID: 26551156 Ref: RAS testing in metastatic colorectal cancer: advances in Europe. PMID: 26573425 Ref: Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. PMID: 26577117 Ref: Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. PMID: 26578731 Ref: MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, KRAS to paclitaxel treatment. PMID: 26581910 Ref: Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. PMID: 26589793 Ref: Identification and characterization of a new G-quadruplex forming region within the kRAS promoter as a transcriptional regulator. PMID: 26597160 Ref: Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. PMID: 26598515 Ref: Associations of red and processed meat with survival after colorectal cancer and differences according to timing of dietary assessment. PMID: 26607936 Ref: KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. PMID: 26610798 Ref: Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. PMID: 26616508 Ref: Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. PMID: 26637197 Ref: Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. PMID: 26644315 Ref: A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. PMID: 26644411 Ref: Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol. PMID: 26646696 Ref: Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. PMID: 26650777 Ref: HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. PMID: 26657506 Ref: Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing. PMID: 26661077 Ref: G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. PMID: 26662311 Ref: A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. PMID: 26666244 Ref: A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. PMID: 26666825 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. PMID: 26701267 Ref: Targeting the PI3K signaling pathway in KRAS mutant colon cancer. PMID: 26715098 Ref: KRAS mutation in lung metastases from colorectal cancer: prognostic implications. PMID: 26715198 Ref: Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. PMID: 26719345 Ref: Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level. PMID: 26735530 Ref: Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. PMID: 26742007 Ref: Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. PMID: 26744320 Ref: Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR. PMID: 26747035 Ref: Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1. PMID: 26747707 Ref: Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. PMID: 26749281 Ref: Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. PMID: 26752111 Ref: A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. PMID: 26759349 Ref: Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers. PMID: 26764183 Ref: Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. PMID: 26775732 Ref: Exploiting the CRISPR/Cas9 PAM Constraint for Single-Nucleotide Resolution Interventions. PMID: 26788852 Ref: [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers]. PMID: 26790710 Ref: Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. PMID: 26798432 Ref: BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. PMID: 26802026 Ref: Mouse models for the discovery of colorectal cancer driver genes. PMID: 26811627 Ref: Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. PMID: 26811634 Ref: Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. PMID: 26812617 Ref: Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. PMID: 26817995 Ref: Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. PMID: 26819545 Ref: HistoMosaic Detecting KRAS G12V Mutation Across Colorectal Cancer Tissue Slices through in Situ PCR. PMID: 26820161 Ref: Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. PMID: 26820797 Ref: Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? PMID: 26824184 Ref: miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. PMID: 26824186 Ref: Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis. PMID: 26824772 Ref: Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status. PMID: 26831663 Ref: Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress. PMID: 26832792 Ref: TNMF versus TNM in staging of colorectal cancer. PMID: 26836283 Ref: Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications. PMID: 26842924 Ref: The State of the Art in Colorectal Cancer Molecular Biomarker Testing. PMID: 26849815 Ref: High PTPRQ Expression and Its Relationship to Expression of PTPRZ1 and the Presence of KRAS Mutations in Colorectal Cancer Tissues. PMID: 26851024 Ref: A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. PMID: 26860615 Ref: Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. PMID: 26867820 Ref: Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 26869800 Ref: The Report of KRAS Mutation and NRAS Wild Type in a Patient with Thyroid Metastasis from Colon Cancer: a Rare Case Report. PMID: 26870147 Ref: Expression of hepatocyte growth factor and c-Met is characteristic of alpha-fetoprotein-producing colorectal adenocarcinoma: A report of three cases. PMID: 26870275 Ref: Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study. PMID: 26870292 Ref: Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. PMID: 26872400 Ref: Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors. PMID: 26880400 Ref: Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. PMID: 26883113 Ref: The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. PMID: 26887348 Ref: Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. PMID: 26892442 Ref: Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. PMID: 26893723 Ref: Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions. PMID: 26910894 Ref: Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. PMID: 26915040 Ref: Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. PMID: 26917275 Ref: Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. PMID: 26925640 Ref: Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran. PMID: 26925650 Ref: Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. PMID: 26927802 Ref: Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. PMID: 26933125 Ref: Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. PMID: 26935130 Ref: Downregulation of epidermal growth factor receptor family receptors and ligands in a mutant K-ras group of patients with colorectal cancer. PMID: 26935861 Ref: Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. PMID: 26938486 Ref: A Crosstalk Between K ras (Kirsten Rat Sarcoma Viral Oncogene Homologue) and Adherence Molecular Complex Leads to Disassociation of Cells-A Possible Contribution Towards Metastasis in Colorectal Cancer. PMID: 26945839 Ref: A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. PMID: 26955660 Ref: MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. PMID: 26957558 Ref: Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. PMID: 26959608 Ref: Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. PMID: 26962170 Ref: Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis. PMID: 26963001 Ref: MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2. PMID: 26968810 Ref: Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. PMID: 26968814 Ref: Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. PMID: 26970738 Ref: A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. PMID: 26975418 Ref: Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. PMID: 26983878 Ref: Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications. PMID: 26984550 Ref: Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer. PMID: 26984642 Ref: BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PMID: 26991109 Ref: Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. PMID: 26991344 Ref: TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors. PMID: 26991699 Ref: Early signet ring cell carcinoma arising from colonic adenoma: the molecular profiling supports the adenoma-carcinoma sequence. PMID: 26997454 Ref: Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/beta-catenin signaling pathway mutations. PMID: 26998897 Ref: Medullary carcinoma in the colorectum: a systematic review and meta-analysis. PMID: 27001432 Ref: Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. PMID: 27002107 Ref: KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. PMID: 27004155 Ref: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. PMID: 27004837 Ref: DDX3 enhances oncogenic KRASinduced tumor invasion in colorectal cancer via the betacatenin/ZEB1 axis. PMID: 27007150 Ref: L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells. PMID: 27012422 Ref: Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. PMID: 27017409 Ref: KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. PMID: 27020587 Ref: Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. PMID: 27026089 Ref: The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer. PMID: 27033063 Ref: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. PMID: 27034809 Ref: Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations. PMID: 27036313 Ref: Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics. PMID: 27037031 Ref: Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. PMID: 27039744 Ref: KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients. PMID: 27043547 Ref: Genotoxicity of Cytolethal Distending Toxin (CDT) on Isogenic Human Colorectal Cell Lines: Potential Promoting Effects for Colorectal Carcinogenesis. PMID: 27047802 Ref: Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. PMID: 27053844 Ref: KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer. PMID: 27062566 Ref: Heterogeneity of KRAS Mutation Status in Rectal Cancer. PMID: 27064574 Ref: [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer]. PMID: 27067688 Ref: [A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab]. PMID: 27067860 Ref: Rapid and Specific Screening Assay for KRAS Oncogene Mutation by a Novel Gene Amplification Method. PMID: 27069133 Ref: The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status. PMID: 27072218 Ref: Prognostic impact of mutation profiling in patients with stage II and III colon cancer. PMID: 27074743 Ref: MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. PMID: 27082577 Ref: Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials. PMID: 27083443 Ref: K-ras gene mutation as an early prognostic marker of colon cancer. PMID: 27096769 Ref: Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PMID: 27101000 Ref: DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance. PMID: 27104828 Ref: Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. PMID: 27108243 Ref: Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. PMID: 27116474 Ref: KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes. PMID: 27117408 Ref: A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. PMID: 27118441 Ref: Vitamin D3 suppresses morphological evolution of the cribriform cancerous phenotype. PMID: 27119498 Ref: Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality? PMID: 27124490 Ref: Interaction of KRAS G-quadruplex with natural polyphenols: A spectroscopic analysis with molecular modeling. PMID: 27130653 Ref: Mucinous epithelial ovarian carcinoma. PMID: 27141073 Ref: BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. PMID: 27143691 Ref: Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. PMID: 27144068 Ref: MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. PMID: 27144434 Ref: (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. PMID: 27146067 Ref: Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. PMID: 27146902 Ref: Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor. PMID: 27149134 Ref: GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. PMID: 27154293 Ref: Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing. PMID: 27155048 Ref: Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer. PMID: 27160084 Ref: Colorectal Cancer Yields to Dual HER2 Blockade. PMID: 27165728 Ref: Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. PMID: 27167191 Ref: Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. PMID: 27167335 Ref: Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. PMID: 27178450 Ref: Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. PMID: 27179112 Ref: Concordance of KRAS mutation status between luminal and peripheral regions of primary colorectal cancer. A laser-capture microdissection-based study. PMID: 27179269 Ref: Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. PMID: 27184911 Ref: In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth. PMID: 27187477 Ref: Clinical impact and network of determinants of tumour necrosis in colorectal cancer. PMID: 27195424 Ref: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. PMID: 27198569 Ref: Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. PMID: 27198570 Ref: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. PMID: 27218826 Ref: Genomic Landscape of Colorectal Mucosa and Adenomas. PMID: 27221540 Ref: Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. PMID: 27221731 Ref: Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. PMID: 27221845 Ref: Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. PMID: 27239120 Ref: Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. PMID: 27244218 Ref: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. PMID: 27246726 Ref: Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. PMID: 27248473 Ref: BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. PMID: 27261210 Ref: The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff? PMID: 27262159 Ref: Isoledene from Mesua ferrea oleo-gum resin induces apoptosis in HCT 116 cells through ROS-mediated modulation of multiple proteins in the apoptotic pathways: A mechanistic study. PMID: 27268964 Ref: Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. PMID: 27270901 Ref: Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. PMID: 27272216 Ref: Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers. PMID: 27275783 Ref: Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. PMID: 27283768 Ref: Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. PMID: 27284437 Ref: Hybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors. PMID: 27289420 Ref: Small-molecule binding of the axin RGS domain promotes beta-catenin and Ras degradation. PMID: 27294323 Ref: Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PMID: 27300552 Ref: A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. PMID: 27302369 Ref: Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. PMID: 27302833 Ref: RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy. PMID: 27305845 Ref: Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. PMID: 27311775 Ref: Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. PMID: 27312529 Ref: Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. PMID: 27323816 Ref: Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. PMID: 27323830 Ref: Molecular pathological classification of colorectal cancer. PMID: 27325016 Ref: FAT1: a potential target for monoclonal antibody therapy in colon cancer. PMID: 27328312 Ref: Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). PMID: 27335808 Ref: A combinatorial strategy for treating KRAS-mutant lung cancer. PMID: 27338794 Ref: Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. PMID: 27340238 Ref: Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment. PMID: 27341591 Ref: Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. PMID: 27342247 Ref: Targeting the serrated pathway of colorectal cancer with mutation in BRAF. PMID: 27345584 Ref: High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. PMID: 27346571 Ref: A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients. PMID: 27347117 Ref: Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. PMID: 27352204 Ref: Distinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer Development. PMID: 27353028 Ref: Caldoramide, a Modified Pentapeptide from the Marine Cyanobacterium Caldora penicillata. PMID: 27380142 Ref: Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. PMID: 27384430 Ref: Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. PMID: 27385211 Ref: Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. PMID: 27391152 Ref: In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. PMID: 27392434 Ref: Mutation spectra of RAS gene family in colorectal cancer. PMID: 27394063 Ref: Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. PMID: 27401719 Ref: Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis. PMID: 27404270 Ref: Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method. PMID: 27405731 Ref: Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature. PMID: 27409671 Ref: HIF-1alpha expression and high microvessel density are characteristic features in serrated colorectal cancer. PMID: 27421843 Ref: Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities. PMID: 27430658 Ref: CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. PMID: 27435270 Ref: A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. PMID: 27438067 Ref: MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas. PMID: 27438990 Ref: Treatment of Metastatic Colorectal Cancer Patients >/=75 Years Old in Clinical Practice: A Multicenter Analysis. PMID: 27442239 Ref: Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. PMID: 27444698 Ref: Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. PMID: 27446446 Ref: First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer. PMID: 27446583 Ref: Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. PMID: 27448974 Ref: KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. PMID: 27449290 Ref: SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. PMID: 27451147 Ref: Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. PMID: 27454043 Ref: GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer. PMID: 27460045 Ref: Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. PMID: 27461218 Ref: Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context. PMID: 27461835 Ref: Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). PMID: 27465221 Ref: Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer. PMID: 27466537 Ref: Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). PMID: 27468920 Ref: Simultaneous destabilization of beta-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer. PMID: 27470214 Ref: Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. PMID: 27472952 Ref: Corrigendum to 'L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells': [Free Radic. Biol. Med. 95 (2016) 200-208]. PMID: 27476024 Ref: Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer". PMID: 27480959 Ref: A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. PMID: 27485514 Ref: miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. PMID: 27494869 Ref: The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. PMID: 27499912 Ref: The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. PMID: 27499922 Ref: Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. PMID: 27499925 Ref: TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. PMID: 27509063 Ref: Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. PMID: 27509333 Ref: Evaluation of KRAS Gene Mutations in Metastatic Colorectal Cancer Patients in Kermanshah Province. PMID: 27509933 Ref: Clinicopathological Features and Survival Rate of Colorectal Adenocarcinoma Patients with and without a KRAS Mutation: a FiveYear Study in Yazd, Iran. PMID: 27509985 Ref: Histoprognostic markers role in colorectal cancer. PMID: 27516017 Ref: Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. PMID: 27521480 Ref: KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer. PMID: 27526107 Ref: Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer. PMID: 27526306 Ref: [A Case of Rectal Neuroendocrine Carcinoma with Metachronous Liver Metastasis Treated with Multimodality Therapy]. PMID: 27539046 Ref: KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. PMID: 27540971 Ref: Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. PMID: 27558481 Ref: High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. PMID: 27562229 Ref: Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. PMID: 27563825 Ref: Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. PMID: 27566022 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. PMID: 27573561 Ref: gamma-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. PMID: 27575851 Ref: FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. PMID: 27575968 Ref: SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. PMID: 27582544 Ref: High expression of the Notch ligand Jagged-1 is associated with poor prognosis after surgery for colorectal cancer. PMID: 27589478 Ref: Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up. PMID: 27591037 Ref: Low expression of PKCalpha and high expression of KRAS predict poor prognosis in patients with colorectal cancer. PMID: 27602102 Ref: Specific inhibition of p110alpha subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. PMID: 27602501 Ref: Current understanding concerning intestinal stem cells. PMID: 27610020 Ref: Study of apoptosis-related interactions in colorectal cancer. PMID: 27629291 Ref: Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. PMID: 27630318 Ref: Prediction of KRAS Mutation in Rectal Cancer Using MRI. PMID: 27630331 Ref: Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. PMID: 27632281 Ref: [Prognostic biomarkers for metastatic colorectal cancer]. PMID: 27638531 Ref: MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. PMID: 27655129 Ref: Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study. PMID: 27656095 Ref: Role of targeted therapy in metastatic colorectal cancer. PMID: 27672422 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: Multi-Center Evaluation of the Fully Automated PCR-Based Idylla KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PMID: 27685259 Ref: FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. PMID: 27685445 Ref: Establishing the colitis-associated cancer progression mouse models. PMID: 27694612 Ref: Generation of an inducible colon-specific Cre enzyme mouse line for colon cancer research. PMID: 27708166 Ref: Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. PMID: 27712015 Ref: BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-kappaB. PMID: 27721019 Ref: A novel E1B55kDa-deleted oncolytic adenovirus carrying microRNA-143 exerts specific antitumor efficacy on colorectal cancer cells. PMID: 27725862 Ref: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. PMID: 27729614 Ref: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. PMID: 27737711 Ref: MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. PMID: 27737877 Ref: Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. PMID: 27747085 Ref: The role of S100a4 (Mts1) in Apc- and Smad4-driven tumour onset and progression. PMID: 27750112 Ref: Cost-effectiveness of cetuximab for colorectal cancer. PMID: 27750444 Ref: Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients Suffering from Colon Cancer by COLD-PCR HRM. PMID: 27753016 Ref: Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. PMID: 27756306 Ref: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. PMID: 27756406 Ref: Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase. PMID: 27764698 Ref: Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. PMID: 27764839 Ref: Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. PMID: 27768923 Ref: MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. PMID: 27769041 Ref: Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. PMID: 27777877 Ref: [Research progress of serrated polyposis syndrome]. PMID: 27781259 Ref: Identification of Binding Targets of a Pyrrole-Imidazole Polyamide KR12 in the LS180 Colorectal Cancer Genome. PMID: 27798693 Ref: KRAS Mutant Status, p16 and beta-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer. PMID: 27798894 Ref: In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells. PMID: 27805251 Ref: Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. PMID: 27827395 Ref: Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. PMID: 27835889 Ref: Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. PMID: 27837635 Ref: Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. PMID: 27843629 Ref: Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. PMID: 27845624 Ref: Deregulation of the miR-16-KRAS axis promotes colorectal cancer. PMID: 27857191 Ref: Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. PMID: 27863403 Ref: Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. PMID: 27863474 Ref: Frequency of K-RAS and N-RAS Gene Mutations in Colorectal Cancers in Southeastern Iran PMID: 27880995 Ref: Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). PMID: 27881709 Ref: Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. PMID: 27892494 Ref: [New Classification for Advanced Colorectal Cancer Using CancerPlex(R)Genomic Tests]. PMID: 27899776 Ref: Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection. PMID: 27900004 Ref: STAT1 Promotes KRAS Colon Tumor Growth and Susceptibility to Pharmacological Inhibition of Translation Initiation Factor eIF4A. PMID: 27913706 Ref: Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. PMID: 27916938 Ref: High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. PMID: 27916952 Ref: Metabolic Adaptation to Nutritional Stress in Human Colorectal Cancer. PMID: 27924922 Ref: Mechanisms underlying (18)F-fluorodeoxyglucose accumulation in colorectal cancer. PMID: 27928469 Ref: Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report. PMID: 27938333 Ref: Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. PMID: 27977612 Ref: Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran. PMID: 27994469 Ref: Clinical Application of Targeted Next Generation Sequencing for Colorectal Cancers. PMID: 27999270 Ref: Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. PMID: 28007036 Ref: Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. PMID: 28008271 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 Ref: Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. PMID: 28078112 Ref: Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. PMID: 28082821 Ref: Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. PMID: 28101205 Ref: miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer. PMID: 28105166 Ref: Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity. PMID: 28105192 Ref: CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. PMID: 28123896 Ref: [A Systematic Analysis of Oncogene and Tumor Suppressor Genes for Panitumumab-Resistant Rectal Cancer with Wild RAS Gene - A Case Report]. PMID: 28133295 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 Ref: Modified mismatch polymerase chain reaction-restriction fragment length polymorphism detected mutations in codon 12 and 13 of exon 2 of K-ras gene in colorectal cancer patients and its association with liver metastases: Data from a South Asian country. PMID: 28169239 Ref: Evaluation and identification of factors related to KRAS and BRAF gene mutations in colorectal cancer: A meta-analysis. PMID: 28230016 Ref: The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases. PMID: 28230018 Ref: Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. PMID: 28356789 Ref: Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. PMID: 28848656 Ref: Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. PMID: 28949453 Ref: Vitamin C, a Multi-Tasking Molecule, Finds a Molecular Target in Killing Cancer Cells. PMID: 29780883 Ref: [Molecular Pathogenesis of Colorectal Cancer]. PMID: 27951718 |
Ref: The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer: A National Study. PMID: 25333735 Ref: Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study. PMID: 25844824 Ref: Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. PMID: 26245851 Ref: Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. PMID: 26461472 Ref: Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. PMID: 26475632 Ref: Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. PMID: 26799287 Ref: NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma. PMID: 26862952 Ref: Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. PMID: 26916220 Ref: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. PMID: 27196573 Ref: BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. PMID: 27354468 Ref: Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. PMID: 27384156 Ref: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. PMID: 27399335 Ref: Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. PMID: 27401248 Ref: RSPO3 expands intestinal stem cell and niche compartments and drives tumorigenesis. PMID: 27511199 Ref: Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. PMID: 27517624 Ref: Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. PMID: 27560620 Ref: Mucinous and Signet Ring Cell Differentiation Affect Patterns of Metastasis in Colorectal Carcinoma and Influence Survival. PMID: 27571790 Ref: Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. PMID: 27578007 Ref: Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. PMID: 27578453 Ref: Gene heterogeneity in metastasis of colorectal cancer to the lung. PMID: 27590223 Ref: Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. PMID: 27600383 Ref: Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates. PMID: 27609830 Ref: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. PMID: 27638675 Ref: Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer. PMID: 27670374 Ref: Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. PMID: 27670890 Ref: Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. PMID: 27681944 Ref: Impact of DNA repair on the dose-response of colorectal cancer formation induced by dietary carcinogens. PMID: 27693244 Ref: Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity. PMID: 27743339 Ref: Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. PMID: 27771609 Ref: Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K). PMID: 27793696 Ref: BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. PMID: 27815357 Ref: Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. PMID: 27836416 Ref: Clinical and genetic determinants of ovarian metastases from colorectal cancer. PMID: 27875625 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. PMID: 27897268 Ref: KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. PMID: 27911859 Ref: Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia. PMID: 27915339 Ref: pathTiMEx: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics. PMID: 27936934 Ref: Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- but not BRAF+ colorectal cancer. PMID: 27943267 Ref: KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. PMID: 27965461 Ref: Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. PMID: 27979717 Ref: Exosomal microRNA concentrations in colorectal cancer: A mathematical model. PMID: 27993628 Ref: LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. PMID: 27999210 Ref: Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. PMID: 28000854 Ref: High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. PMID: 28000889 Ref: Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. PMID: 28002797 Ref: Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. PMID: 28002807 Ref: Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. PMID: 28004119 Ref: Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. PMID: 28006055 Ref: Clinical relevance of colorectal cancer molecular subtypes. PMID: 28010901 Ref: Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. PMID: 28011498 Ref: Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. PMID: 28025078 Ref: EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. PMID: 28025786 Ref: Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. PMID: 28031175 Ref: Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. PMID: 28040692 Ref: Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. PMID: 28040715 Ref: Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. PMID: 28045335 Ref: Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. PMID: 28058585 Ref: Translating genomic profiling to gastrointestinal cancer treatment. PMID: 28067073 Ref: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. PMID: 28068936 Ref: KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. PMID: 28074351 Ref: KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. PMID: 28077799 Ref: Conformational SERS Classification of K-Ras Point Mutations for Cancer Diagnostics. PMID: 28079954 Ref: Molecular subtypes of colorectal cancers determined by PCR-based analysis. PMID: 28083970 Ref: Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. PMID: 28091917 Ref: Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. PMID: 28095174 Ref: Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer. PMID: 28097409 Ref: The Role of Liquid Based Cytology and Ancillary Techniques in the Peritoneal Washing Analysis: Our Institutional Experience. PMID: 28099523 Ref: [Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system]. PMID: 28105615 Ref: Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. PMID: 28106826 Ref: The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PMID: 28125730 Ref: Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer. PMID: 28145097 Ref: EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. PMID: 28147317 Ref: Gene Silencing Using Multifunctionalized Gold Nanoparticles for Cancer Therapy. PMID: 28150211 Ref: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. PMID: 28152546 Ref: QMC-PCRx: a novel method for rapid mutation detection. PMID: 28153952 Ref: USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. PMID: 28154181 Ref: Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. PMID: 28154202 Ref: Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs. PMID: 28167959 Ref: Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. PMID: 28170370 Ref: Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. PMID: 28173629 Ref: Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. PMID: 28179313 Ref: Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. PMID: 28179590 Ref: Gene expression changes in colon tissues from colorectal cancer patients following the intake of an ellagitannin-containing pomegranate extract: a randomized clinical trial. PMID: 28183047 Ref: Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. PMID: 28184012 Ref: Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutationsdagger. PMID: 28186237 Ref: KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. PMID: 28188750 Ref: A novel RNA sequencing data analysis method for cell line authentication. PMID: 28192450 Ref: Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples. PMID: 28201998 Ref: Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations. PMID: 28202525 Ref: Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. PMID: 28208157 Ref: Detecting circulating tumor DNA in renal cancer: An open challenge. PMID: 28214514 Ref: KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. PMID: 28215705 Ref: Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. PMID: 28216246 Ref: Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer. PMID: 28218473 Ref: Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes. PMID: 28218784 Ref: Molecular Testing for Gastrointestinal Cancer. PMID: 28219002 Ref: Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. PMID: 28222664 Ref: Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report. PMID: 28228152 Ref: Clinical Application of Liquid Biopsy in Targeted Therapy of Metastatic Colorectal Cancer. PMID: 28232873 Ref: Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. PMID: 28235632 Ref: Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. PMID: 28241877 Ref: CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype. PMID: 28242812 Ref: Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. PMID: 28243130 Ref: Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. PMID: 28243320 Ref: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. PMID: 28246207 Ref: Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. PMID: 28249812 Ref: miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. PMID: 28259135 Ref: Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of KRAS-wildtype rectal cancer. PMID: 28260928 Ref: A novel KRAS gene mutation report in sporadic colorectal cancer, from Northwest of Iran. PMID: 28265402 Ref: Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PMID: 28267766 Ref: Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. PMID: 28268248 Ref: Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. PMID: 28275037 Ref: Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. PMID: 28278514 Ref: Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 28280091 Ref: Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). PMID: 28280603 Ref: Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience. PMID: 28280609 Ref: Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. PMID: 28280616 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. PMID: 28280626 Ref: Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. PMID: 28283541 Ref: Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. PMID: 28289141 Ref: Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC. PMID: 28292978 Ref: CD95 ligand induces senescence in mismatch repair-deficient human colon cancer via chronic caspase-mediated induction of DNA damage. PMID: 28300842 Ref: In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. PMID: 28301591 Ref: Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. PMID: 28314271 Ref: KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer. PMID: 28314302 Ref: Intratumorous heterogeneity for RAS mutations in a treatment-naive colorectal tumour. PMID: 28314739 Ref: No back seat for a progression event-K-RAS as a therapeutic target in CRC. PMID: 28314765 Ref: miR-134: A Human Cancer Suppressor? PMID: 28325280 Ref: Sessile Serrated Polyps and Colon Cancer Prevention. PMID: 28325827 Ref: Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). PMID: 28327908 Ref: KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer. PMID: 28328959 Ref: Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor. PMID: 28339087 Ref: Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers. PMID: 28345467 Ref: Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. PMID: 28353122 Ref: SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma. PMID: 28353383 Ref: The significance of DNA methylation profile in metastasis-related genes for the progression of colorectal cancer. PMID: 28364795 Ref: Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer. PMID: 28365952 Ref: Methods of selecting combination therapy for colorectal cancer patients: a patent evaluation of US20160025730A1. PMID: 28366103 Ref: TGFbeta engages MEK/ERK to differentially regulate benign and malignant pancreas cell function. PMID: 28368414 Ref: DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. PMID: 28378457 Ref: Performance of a Web-based Method for Generating Synoptic Reports. PMID: 28382227 Ref: Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping. PMID: 28398227 Ref: Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors. PMID: 28403349 Ref: Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. PMID: 28405513 Ref: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. PMID: 28406723 Ref: Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients. PMID: 28411881 Ref: Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. PMID: 28415695 Ref: The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients. PMID: 28416767 Ref: Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer. PMID: 28418176 Ref: Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer. PMID: 28422714 Ref: Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. PMID: 28424871 Ref: Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach. PMID: 28429715 Ref: NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer. PMID: 28433252 Ref: The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer. PMID: 28435452 Ref: Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and beta-catenin immunostaining for differentiation from metastatic colorectal carcinoma. PMID: 28438615 Ref: Selective eradication of cancer cells by delivery of adenovirus-based toxins. PMID: 28445136 Ref: Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. PMID: 28446505 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. PMID: 28451421 Ref: Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. PMID: 28453690 Ref: Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. PMID: 28453697 Ref: In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. PMID: 28459449 Ref: Genome-wide DNA methylation profiling reveals cancer-associated changes within early colonic neoplasia. PMID: 28459462 Ref: Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. PMID: 28459468 Ref: Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PMID: 28459822 Ref: HMG-CoA synthase 1 is a synthetic lethal partner of BRAF(V600E) in human cancers. PMID: 28468827 Ref: Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. PMID: 28473715 Ref: MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. PMID: 28475173 Ref: Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. PMID: 28476018 Ref: Associating transcriptional modules with colon cancer survival through weighted gene co-expression network analysis. PMID: 28486948 Ref: Future perspectives of circulating tumor DNA in colorectal cancer. PMID: 28488528 Ref: Endoscopic and molecular characterization of colorectal sessile serrated adenoma/polyps with cytologic dysplasia. PMID: 28501592 Ref: What We Know About Stage II and III Colon Cancer: It's Still Not Enough. PMID: 28504299 Ref: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. PMID: 28507204 Ref: Retraction: Evaluation and identification of factors related to KRAS and BRAF gene mutations in colorectal cancer: A meta analysis. PMID: 28508855 Ref: Statin Use After Diagnosis of Colon Cancer and Patient Survival. PMID: 28512021 Ref: A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. PMID: 28512242 Ref: Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. PMID: 28513830 Ref: KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population. PMID: 28521461 Ref: Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. PMID: 28524155 Ref: Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. PMID: 28524162 Ref: Phospholipase C delta1 negatively regulates autophagy in colorectal cancer cells. PMID: 28528980 Ref: Gender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer. PMID: 28531253 Ref: [A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases]. PMID: 28536339 Ref: Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer. PMID: 28540987 Ref: Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. PMID: 28548123 Ref: A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. PMID: 28551381 Ref: Influence of mucinous and necrotic tissue in colorectal cancer samples on KRAS mutation analysis. PMID: 28551386 Ref: MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. PMID: 28551618 Ref: The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells. PMID: 28560069 Ref: EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. PMID: 28560458 Ref: Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. PMID: 28561063 Ref: Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. PMID: 28567185 Ref: The novel hypoxia-inducible factor-1alpha inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth. PMID: 28569777 Ref: Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation. PMID: 28579802 Ref: The Epigenomics of Embryonic Pathway Signaling in Colorectal Cancer. PMID: 28579957 Ref: Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. PMID: 28580315 Ref: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. PMID: 28583095 Ref: Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. PMID: 28593995 Ref: Colorectal cancer in cases of multiple primary cancers: Clinical features of 59 cases and point mutation analyses. PMID: 28599473 Ref: Mucosa-associated microbiota signature in colorectal cancer. PMID: 28600626 Ref: A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. PMID: 28611106 Ref: Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. PMID: 28611205 Ref: Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. PMID: 28612017 Ref: Prevalence of pks-positive Escherichia coli in Japanese patients with or without colorectal cancer. PMID: 28616082 Ref: Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. PMID: 28617623 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. PMID: 28618197 Ref: Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. PMID: 28618430 Ref: Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same. PMID: 28632850 Ref: First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). PMID: 28633089 Ref: SensiScreen(R)KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations. PMID: 28636636 Ref: Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Prognosis in Colorectal Cancers. PMID: 28638266 Ref: Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits. PMID: 28639239 Ref: Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PMID: 28640835 Ref: Mutational Heterogeneity in APC and KRAS Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis. PMID: 28645942 Ref: Application of open-access databases to determine functional connectivity between resveratrol-binding protein QR2 and colorectal carcinoma. PMID: 28646291 Ref: Associations of red and processed meat intake with major molecular pathological features of colorectal cancer. PMID: 28646407 Ref: Targeting metabolic reprogramming in KRAS-driven cancers. PMID: 28647837 Ref: K-ras Mutations as the Earliest Driving Force in a Subset of Colorectal Carcinomas. PMID: 28652417 Ref: RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). PMID: 28653203 Ref: PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. PMID: 28659148 Ref: Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? PMID: 28665451 Ref: Clinicopathological and Corresponding Genetic Features of Colorectal Signet Ring Cell Carcinoma. PMID: 28668881 Ref: Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS. PMID: 28668883 Ref: An Alpha-kinase 2 Gene Variant Disrupts Filamentous Actin Localization in the Surface Cells of Colorectal Cancer Spheroids. PMID: 28668886 Ref: Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. PMID: 28671043 Ref: Wildtype blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS. PMID: 28677778 Ref: Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. PMID: 28678173 Ref: Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. PMID: 28685087 Ref: A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer. PMID: 28685354 Ref: Coffee reduces KRAS expression in Caco-2 human colon carcinoma cells via regulation of miRNAs. PMID: 28693281 Ref: Molecular genetic changes in benign colorectal tumors synchronous with microsatellite unstable carcinomas do not support a field defect. PMID: 28694923 Ref: Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. PMID: 28695301 Ref: The value of (18)FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer. PMID: 28697193 Ref: Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer. PMID: 28708207 Ref: Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. PMID: 28711984 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. PMID: 28748988 Ref: Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. PMID: 28749408 Ref: Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs). PMID: 28755485 Ref: A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. PMID: 28759160 Ref: TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. PMID: 28760399 Ref: A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. PMID: 28775144 Ref: Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. PMID: 28778958 Ref: Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. PMID: 28783173 Ref: Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. PMID: 28784880 Ref: Squirrel Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments. PMID: 28785174 Ref: Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. PMID: 28791253 Ref: Recent developments in the treatment of metastatic colorectal cancer. PMID: 28794806 Ref: The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. PMID: 28796802 Ref: Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer. PMID: 28800074 Ref: Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. PMID: 28801584 Ref: A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PMID: 28806777 Ref: The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. PMID: 28807001 Ref: Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. PMID: 28811946 Ref: Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. PMID: 28835536 Ref: Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis. PMID: 28850092 Ref: Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. PMID: 28856682 Ref: Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. PMID: 28858102 Ref: Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. PMID: 28859058 Ref: Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding. PMID: 28863773 Ref: Using Naive Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. PMID: 28869500 Ref: Colitic Cancer Develops Through Mutational Alteration Distinct from that in Sporadic Colorectal Cancer: A Comparative Analysis of Mutational Rates at Each Step. PMID: 28871001 Ref: The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis. PMID: 28881837 Ref: Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis. PMID: 28885658 Ref: A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. PMID: 28894396 Ref: Implementation and utilization of the molecular tumor board to guide precision medicine. PMID: 28915716 Ref: Upregulation of Cystathionine-beta-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes Carcinogenesis. PMID: 28923859 Ref: The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 28928870 Ref: Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. PMID: 28931905 Ref: Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. PMID: 28932083 Ref: EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. PMID: 28936923 Ref: Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. PMID: 28939741 Ref: Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. PMID: 28942013 Ref: Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and autophagic interference in colorectal cancer. PMID: 28943451 Ref: Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers. PMID: 28954733 Ref: High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PMID: 28957395 Ref: What Is Different in the Population of the Brazilian Amazon Region so that They Have a Low Frequency of KRAS Gene Mutations? PMID: 28966582 Ref: Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. PMID: 28978093 Ref: KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care. PMID: 28979819 Ref: Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PMID: 28981524 Ref: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. PMID: 29024937 Ref: Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. PMID: 29029407 Ref: Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. PMID: 29029414 Ref: Colorectal carcinoma with osseous metaplasia. PMID: 29029440 Ref: Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis. PMID: 29029527 Ref: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. PMID: 29037218 Ref: Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. PMID: 29038297 Ref: Increased Frequency of KRAS Mutations in African Americans Compared with Caucasians in Sporadic Colorectal Cancer. PMID: 29048416 Ref: MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis. PMID: 29048575 Ref: MicroRNA337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways. PMID: 29048669 Ref: [Anti-EGFR Antibody Combination Chemotherapy Was Effective against Locally Advanced Ascending Colon Cancer as Well as a Recurrent Lesion - A Case Report]. PMID: 29066705 Ref: A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. PMID: 29067643 Ref: Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer. PMID: 29069792 Ref: POLE somatic mutations in advanced colorectal cancer. PMID: 29072370 Ref: KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. PMID: 29085005 Ref: Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. PMID: 29085667 Ref: Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR. PMID: 29093617 Ref: Establishing a colorectal cancer liver metastasis patient-derived tumor xenograft model for the evaluation of personalized chemotherapy. PMID: 29094026 Ref: Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review. PMID: 29096939 Ref: Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. PMID: 29100436 Ref: Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer. PMID: 29111094 Ref: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. PMID: 29115941 Ref: Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. PMID: 29127628 Ref: Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics. PMID: 29137388 Ref: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. PMID: 29137623 Ref: TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy. PMID: 29145973 Ref: Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. PMID: 29156792 Ref: Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells. PMID: 29160412 Ref: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. PMID: 29169325 Ref: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review. PMID: 29183279 Ref: Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects. PMID: 29192596 Ref: TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis. PMID: 29199261 Ref: KRAS biomarker testing disparities in colorectal cancer patients in New Mexico. PMID: 29202108 Ref: Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre. PMID: 29203982 Ref: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. PMID: 29212173 Ref: Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. PMID: 29212194 Ref: Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). PMID: 29213343 Ref: Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. PMID: 29222441 Ref: KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. PMID: 29223986 Ref: LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer. PMID: 29254168 Ref: Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. PMID: 29262612 Ref: [Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture]. PMID: 29263461 Ref: Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer. PMID: 29279709 Ref: Study of the role of telomerase in colorectal cancer: preliminary report and literature review. PMID: 29280699 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry. PMID: 29372103 Ref: [A Case of Ascending Colon Cancer with Synchronous Liver Metastases and Peritoneal Dissemination]. PMID: 29394555 Ref: [Case Report of Long-Term Survival for Stage IV Advanced Sigmoid Colon Cancer with Para-Aortic Nodes by R0 Resection and Chemotherapy]. PMID: 29394654 Ref: Increased Efficacy of Stereotactic Ablative Radiation Therapy after Bevacizumab in Lung Oligometastases from Colon Cancer. PMID: 29737958 |
Ref: The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. PMID: 27258560 Ref: Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort. PMID: 28044264 Ref: Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. PMID: 28262927 Ref: Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer. PMID: 28277374 Ref: How accurate are medical oncologists' impressions of management of metastatic colorectal cancer in Australia? PMID: 28299879 Ref: Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. PMID: 28359236 Ref: Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials? PMID: 28432610 Ref: Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. PMID: 28746977 Ref: Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. PMID: 28823057 Ref: Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. PMID: 28877066 Ref: Clinicopathological and molecular implications of aberrant thyroid transcription factor-1 expression in colorectal carcinomas: an immunohistochemical analysis of 1319 cases using three different antibody clones. PMID: 28914964 Ref: Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. PMID: 28921583 Ref: A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation. PMID: 28936721 Ref: RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. PMID: 28950295 Ref: Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity. PMID: 29027537 Ref: FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer. PMID: 29046927 Ref: Association between clinicopathological characteristics and RAS mutation in colorectal cancer. PMID: 29052598 Ref: KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. PMID: 29061646 Ref: BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922. PMID: 29068469 Ref: Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. PMID: 29075780 Ref: Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. PMID: 29104111 Ref: Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? PMID: 29118162 Ref: Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. PMID: 29128266 Ref: Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient-derived spheroid cultures. PMID: 29130628 Ref: Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. PMID: 29180604 Ref: RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. PMID: 29196555 Ref: Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression. PMID: 29207158 Ref: Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression. PMID: 29222172 Ref: Molecular profiling and genome-wide analysis based on somatic copy number alterations in advanced colorectal cancers. PMID: 29230882 Ref: Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. PMID: 29233486 Ref: Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma. PMID: 29240583 Ref: Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). PMID: 29241084 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. PMID: 29267900 Ref: Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer. PMID: 29282223 Ref: Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. PMID: 29282362 Ref: Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. PMID: 29301589 Ref: Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform. PMID: 29304017 Ref: Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. PMID: 29304903 Ref: Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. PMID: 29306042 Ref: Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. PMID: 29313389 Ref: Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. PMID: 29316426 Ref: Mutations of key driver genes in colorectal cancer progression and metastasis. PMID: 29322354 Ref: Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. PMID: 29327707 Ref: RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. PMID: 29333594 Ref: Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? PMID: 29335867 Ref: MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights. PMID: 29337244 Ref: Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. PMID: 29338072 Ref: MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers. PMID: 29374690 Ref: A Low-Cost Palmtop High-Speed Capillary Electrophoresis Bioanalyzer with Laser Induced Fluorescence Detection. PMID: 29379053 Ref: A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing. PMID: 29380513 Ref: Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. PMID: 29380640 Ref: Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. PMID: 29382774 Ref: Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. PMID: 29386984 Ref: Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. PMID: 29388061 Ref: Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. PMID: 29397354 Ref: Phosphatidylinositol 3-Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. PMID: 29401002 Ref: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. PMID: 29402316 Ref: Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer. PMID: 29403291 Ref: Spectrum of APC and MUTYH germ-line mutations in Russian patients with colorectal malignancies. PMID: 29406563 Ref: KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. PMID: 29409955 Ref: Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? PMID: 29414818 Ref: Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling. PMID: 29416670 Ref: Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China. PMID: 29423347 Ref: Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. PMID: 29424427 Ref: Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. PMID: 29431699 Ref: Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. PMID: 29435051 Ref: Epigenetic silencing of SMOC1 in traditional serrated adenoma and colorectal cancer. PMID: 29435136 Ref: Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. PMID: 29438965 Ref: Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. PMID: 29439113 Ref: Interaction of the Wnt/beta-catenin and RAS-ERK pathways involving co-stabilization of both beta-catenin and RAS plays important roles in the colorectal tumorigenesis. PMID: 29449169 Ref: PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. PMID: 29449544 Ref: Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer? PMID: 29450716 Ref: Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. PMID: 29452147 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies. PMID: 29478126 Ref: The role of TGF-beta/SMAD4 signaling in cancer. PMID: 29483830 Ref: Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients. PMID: 29484148 Ref: Systemic Therapy for Colon Cancer. PMID: 29496087 Ref: Clinical Trials and Progress in Metastatic Colon Cancer. PMID: 29496094 Ref: Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer. PMID: 29496312 Ref: Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. PMID: 29498789 Ref: Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. PMID: 29507676 Ref: New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. PMID: 29507677 Ref: A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. PMID: 29508026 Ref: Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study. PMID: 29511559 Ref: Targeting a Sirt5-Positive Subpopulation Overcomes Multidrug Resistance in Wild-Type Kras Colorectal Carcinomas. PMID: 29514096 Ref: CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. PMID: 29518181 Ref: Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). PMID: 29523646 Ref: APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. PMID: 29525853 Ref: Phosphorylation of p70 Ribosomal Protein S6 Kinase beta-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. PMID: 29526493 Ref: Monitoring colorectal cancer following surgery using plasma circulating tumor DNA. PMID: 29541205 Ref: A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-kappaB Signaling in KRAS-Mutant Colon Cancer Cells. PMID: 29545333 Ref: The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. PMID: 29546405 Ref: Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation. PMID: 29549923 Ref: beta-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. PMID: 29551770 Ref: Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients. PMID: 29556349 Ref: Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. PMID: 29559746 Ref: Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. PMID: 29575536 Ref: [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR]. PMID: 29577691 Ref: Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? PMID: 29580164 Ref: FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. PMID: 29587749 Ref: Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. PMID: 29596542 Ref: Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. PMID: 29610327 Ref: A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer. PMID: 29619072 Ref: Omega-3 fatty acid DHA modulates p53, survivin, and microRNA-16-1 expression in KRAS-mutant colorectal cancer stem-like cells. PMID: 29619114 Ref: [Prediction of EGFR blockade responses in metastatic colorectal carcinoma]. PMID: 29631407 Ref: Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location. PMID: 29632645 Ref: Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. PMID: 29643917 Ref: Phenotypic and genotypic differences in colorectal carcinoma among Caucasians, Asians, and Hispanics lack statistical significance. PMID: 29650442 Ref: Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. PMID: 29662660 Ref: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. PMID: 29666387 Ref: Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. PMID: 29682243 Ref: Identification of key pathways and genes in mutant KRAS colorectal cancer by integrated bioinformatics analysis. PMID: 29688256 Ref: One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status. PMID: 29694444 Ref: Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes. PMID: 29697365 Ref: Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status. PMID: 29703759 Ref: Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. PMID: 29705968 Ref: RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. PMID: 29707525 Ref: Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. PMID: 29715113 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Update on Sporadic Colorectal Cancer Genetics. PMID: 29720900 Ref: Correction: New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. PMID: 29722369 Ref: Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. PMID: 29725370 Ref: Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma. PMID: 29729192 Ref: Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. PMID: 29731264 Ref: A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype. PMID: 29743592 Ref: Site-specific use of molecular markers could be a promising prognostic tool in colorectal cancer. PMID: 29745066 Ref: Oncogenic KRAS suppresses store-operated Ca(2+) entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines. PMID: 29748135 Ref: Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. PMID: 29755130 Ref: Hotspot KRAS exon 2 mutations in CD166 positive colorectal cancer and colorectal adenoma cells. PMID: 29755662 Ref: Role of epigenetic factors in the selection of the alternative splicing isoforms of human KRAS in colorectal cancer cell lines. PMID: 29755673 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2. PMID: 29758216 Ref: The role of heme iron molecules derived from red and processed meat in the pathogenesis of colorectal carcinoma. PMID: 29759553 Ref: Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer. PMID: 29760449 Ref: Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy). PMID: 29765524 Ref: Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. PMID: 29767751 Ref: Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition. PMID: 29769200 Ref: Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018. PMID: 29776633 Ref: Anatomical Resections Improve Survival Following Lung Metastasectomy of Colorectal Cancer Harboring KRAS Mutations. PMID: 29781848 Ref: Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. PMID: 29788391 Ref: Novel insights into transcriptional dysregulation in colorectal cancer. PMID: 29788743 Ref: Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care. PMID: 29790787 Ref: Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. PMID: 29793804 Ref: Comprehensive molecular analysis based on somatic copy number alterations in intramucosal colorectal neoplasias and early invasive colorectal cancers. PMID: 29796160 Ref: Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. PMID: 29799910 Ref: Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. PMID: 29802524 Ref: The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. PMID: 29805705 Ref: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. PMID: 29808006 Ref: Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. PMID: 29844874 Ref: In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer. PMID: 29851214 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. PMID: 29855806 Ref: Interaction between Wnt/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt/beta-catenin pathway. PMID: 29872723 Ref: Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition. PMID: 29873882 Ref: Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PMID: 29879227 Ref: Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PMID: 29883450 Ref: Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of beta-catenin signaling. PMID: 29884842 Ref: Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells. PMID: 29896883 Ref: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. PMID: 29900052 Ref: Assessment of Digital PCR as a Primary Reference Measurement Procedure to Support Advances in Precision Medicine. PMID: 29903874 Ref: Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. PMID: 29907857 Ref: Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. PMID: 29908105 Ref: Colorectal cancer genomics and designing rational trials. PMID: 29911107 Ref: PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. PMID: 29915291 Ref: Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients. PMID: 29921458 Ref: The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the 'unexplainable'. PMID: 29927360 Ref: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. PMID: 29937183 Ref: The landscape of somatic mutation in sporadic Chinese colorectal cancer. PMID: 29937994 Ref: Mutational status of KRAS and MMR genes in a series of colorectal carcinoma cases. PMID: 29940619 Ref: Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). PMID: 29941002 Ref: Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. PMID: 29945573 Ref: Cancer-associated fibroblasts enhance cell proliferation and metastasis of colorectal cancer SW480 cells by provoking long noncoding RNA UCA1. PMID: 29948578 Ref: Metabolic Imaging Phenotype Using Radiomics of [(18)F]FDG PET/CT Associated with Genetic Alterations of Colorectal Cancer. PMID: 29948642 Ref: Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. PMID: 29959022 Ref: Dynamics of Genome Alterations in Crohn's Disease-Associated Colorectal Carcinogenesis. PMID: 29967250 Ref: Growth Suppression of Human Colorectal Cancer Cells with Mutated KRAS by 3-Deaza-cytarabine in 3D Floating Culture. PMID: 29970558 Ref: Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. PMID: 29970575 Ref: ANIMAL MODELS FOR COLORECTAL CANCER. PMID: 29972397 Ref: Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. PMID: 29985199 Ref: [Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies]. PMID: 29996313 Ref: Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PMID: 30001368 Ref: Genome doubling shapes the evolution and prognosis of advanced cancers. PMID: 30013179 Ref: Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients. PMID: 30016269 Ref: Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. PMID: 30023463 Ref: [A Case of Postoperative Recurrence of Rectal Cancer in Which Desensitization Therapy Was Effective against Oxaliplatin Allergy in L-OHP]. PMID: 30026456 Ref: Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. PMID: 30029640 Ref: The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. PMID: 30035653 Ref: Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. PMID: 30036146 Ref: Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression. PMID: 30036518 Ref: RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. PMID: 30037330 Ref: A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer. PMID: 30038269 Ref: Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. PMID: 30042065 Ref: HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. PMID: 30056472 Ref: Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. PMID: 30071442 Ref: Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. PMID: 30073936 Ref: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. PMID: 30085422 Ref: Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. PMID: 30087121 Ref: A natural flavonoid lawsonaringenin induces cell cycle arrest and apoptosis in HT-29 colorectal cancer cells by targeting multiple signalling pathways. PMID: 30088202 Ref: A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer. PMID: 30088781 Ref: EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer. PMID: 30096327 Ref: Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression. PMID: 30104206 Ref: Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. PMID: 30106444 Ref: Association of Clinicopathologic and Molecular Markers on Stage-specific Survival of Right Versus Left Colon Cancer. PMID: 30108021 Ref: Fos-like antigen 2 (FOSL2) promotes metastasis in colon cancer. PMID: 30114390 Ref: Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. PMID: 30116425 Ref: Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations. PMID: 30118499 Ref: Protocadherin gamma A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS. PMID: 30121367 Ref: Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. PMID: 30121958 Ref: Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. PMID: 30123970 Ref: Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates. PMID: 30130797 Ref: COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS. PMID: 30132520 Ref: Main Risk Factors Association with Proto-Oncogene Mutations in Colorectal Cancer PMID: 30139223 Ref: Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). PMID: 30150883 Ref: Novel beta-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer. PMID: 30158525 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: Multispectral Near-Infrared Optical Tomography for Cancer Hypoxia Study in Mice. PMID: 30178340 Ref: Histogram Analysis of Perfusion Parameters from Dynamic Contrast-Enhanced MR Imaging with Tumor Characteristics and Therapeutic Response in Locally Advanced Rectal Cancer. PMID: 30186857 Ref: Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PMID: 30188916 Ref: PDEdelta inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. PMID: 30194764 Ref: First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs. PMID: 30196427 Ref: Clinical update on K-Ras targeted therapy in gastrointestinal cancers. PMID: 30196915 Ref: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. PMID: 30202242 Ref: Variability in HER2 expression between primary colorectal cancer and corresponding metastases. PMID: 30203148 Ref: Quercetin preferentially induces apoptosis in KRAS-mutant colorectal cancer cells via JNK signaling pathways. PMID: 30203888 Ref: Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. PMID: 30205948 Ref: Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis. PMID: 30214286 Ref: Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications. PMID: 30217071 Ref: Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. PMID: 30217306 Ref: Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. PMID: 30219720 Ref: The frequency of promoter DNA hypermethylation is decreased in colorectal neoplasms of familial adenomatous polyposis. PMID: 30220972 Ref: EGF ligand fused to truncated Pseudomonas aeruginosa exotoxin A specifically targets and inhibits EGFRpositive cancer cells. PMID: 30226622 Ref: Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. PMID: 30228205 Ref: Data on tumor progression of c-mos deficiency in murine models of Kras(G12D) lung and Apc(Min) colorectal cancer. PMID: 30229128 Ref: Elevated G-Protein Receptor 125 (GPR125) Expression Predicts Good Outcomes in Colorectal Cancer and Inhibits Wnt/beta-Catenin Signaling Pathway. PMID: 30231258 Ref: Liquid Biopsy to Identify Actionable Genomic Alterations. PMID: 30231331 Ref: Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. PMID: 30231342 Ref: Exome scale map of genetic alterations promoting metastasis in colorectal cancer. PMID: 30231850 Ref: Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. PMID: 30233821 Ref: The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. PMID: 30243655 Ref: Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancer. PMID: 30252132 Ref: Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD databas PMID: 30268921 Ref: Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. PMID: 30271205 Ref: Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. PMID: 30275173 Ref: The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases. PMID: 30276588 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 Ref: Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer. PMID: 30311185 Ref: Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. PMID: 30315134 Ref: The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death. PMID: 30318510 Ref: Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. PMID: 30318772 Ref: LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. PMID: 30320451 Ref: Diverse Long RNAs Are Differentially Sorted into Extracellular Vesicles Secreted by Colorectal Cancer Cells. PMID: 30332650 Ref: EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer. PMID: 30333883 Ref: Circulating cell-free DNA- diagnostic and prognostic applications in personalized cancer therapy. PMID: 30335711 Ref: Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. PMID: 30336540 Ref: Microfluidic-based solid phase extraction of cell free DNA. PMID: 30339164 Ref: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. PMID: 30339194 Ref: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer. PMID: 30340556 Ref: Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. PMID: 30341899 Ref: Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. PMID: 30342037 Ref: Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. PMID: 30344942 Ref: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. PMID: 30353166 Ref: Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. PMID: 30356899 Ref: Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. PMID: 30358195 Ref: Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific. PMID: 30361395 Ref: Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog -mutant colorectal cancer. PMID: 30362665 Ref: Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). PMID: 30366852 Ref: Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. PMID: 30370522 Ref: Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection. PMID: 30378010 Ref: The small organic molecule C19 binds and strengthens the KRAS4b-PDEdelta complex and inhibits growth of colorectal cancer cells in vitro and in vivo. PMID: 30382908 Ref: Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. PMID: 30385823 Ref: Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. PMID: 30388256 |